CN113774031B - 一种复制型人腺病毒及其应用 - Google Patents
一种复制型人腺病毒及其应用 Download PDFInfo
- Publication number
- CN113774031B CN113774031B CN202010523284.8A CN202010523284A CN113774031B CN 113774031 B CN113774031 B CN 113774031B CN 202010523284 A CN202010523284 A CN 202010523284A CN 113774031 B CN113774031 B CN 113774031B
- Authority
- CN
- China
- Prior art keywords
- delta
- genome
- e3gp19k
- srfi
- nbov1901
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000010076 replication Effects 0.000 title claims abstract description 35
- 241000598171 Human adenovirus sp. Species 0.000 title claims abstract description 21
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 49
- 239000013598 vector Substances 0.000 claims abstract description 45
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 239000013612 plasmid Substances 0.000 claims description 80
- 239000012634 fragment Substances 0.000 claims description 46
- 108090000623 proteins and genes Proteins 0.000 claims description 40
- 238000012408 PCR amplification Methods 0.000 claims description 29
- 238000010276 construction Methods 0.000 claims description 17
- 101150098847 pRB gene Proteins 0.000 claims description 15
- 238000001976 enzyme digestion Methods 0.000 claims description 13
- 238000011144 upstream manufacturing Methods 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 230000004957 immunoregulator effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000001126 phototherapy Methods 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 abstract description 33
- 230000000174 oncolytic effect Effects 0.000 abstract description 30
- 150000007523 nucleic acids Chemical group 0.000 abstract description 6
- 230000002147 killing effect Effects 0.000 abstract description 5
- 210000005260 human cell Anatomy 0.000 abstract description 3
- 238000011068 loading method Methods 0.000 abstract description 2
- 241000701161 unidentified adenovirus Species 0.000 description 44
- 210000004027 cell Anatomy 0.000 description 35
- 241000700605 Viruses Species 0.000 description 28
- 108020004414 DNA Proteins 0.000 description 25
- 238000012216 screening Methods 0.000 description 16
- 230000029087 digestion Effects 0.000 description 15
- 229960000723 ampicillin Drugs 0.000 description 14
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 11
- 238000002744 homologous recombination Methods 0.000 description 10
- 230000006801 homologous recombination Effects 0.000 description 10
- 238000003776 cleavage reaction Methods 0.000 description 8
- 229930027917 kanamycin Natural products 0.000 description 8
- 229960000318 kanamycin Drugs 0.000 description 8
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 8
- 229930182823 kanamycin A Natural products 0.000 description 8
- 244000309459 oncolytic virus Species 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 230000006798 recombination Effects 0.000 description 7
- 238000005215 recombination Methods 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 6
- 101150029662 E1 gene Proteins 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 102000018120 Recombinases Human genes 0.000 description 5
- 108010091086 Recombinases Proteins 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 4
- 101710114676 E1B 55 kDa protein Proteins 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 206010017758 gastric cancer Diseases 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 201000011549 stomach cancer Diseases 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 208000032420 Latent Infection Diseases 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 239000013605 shuttle vector Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 241000701242 Adenoviridae Species 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 108050002653 Retinoblastoma protein Proteins 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 2
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 108700010877 adenoviridae proteins Proteins 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 239000010420 shell particle Substances 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000005723 virus inoculator Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 101150096316 5 gene Proteins 0.000 description 1
- 108010087905 Adenovirus E1B Proteins Proteins 0.000 description 1
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 102100021251 Beclin-1 Human genes 0.000 description 1
- 108090000524 Beclin-1 Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 201000001342 Fallopian tube cancer Diseases 0.000 description 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 241001334146 Rugopharynx delta Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 108700041737 bcl-2 Genes Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000037455 tumor specific immune response Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
- C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种复制型人腺病毒及其应用。载体全序列如SEQ ID NO.21所示。本发明一些实例所述的复制型人腺病毒,在负载相关核酸序列后,可以直接注射于实体肿瘤,包括但不限于H1299,还包括Skov‑3、U251等肿瘤后,经鉴定,该腺病毒不仅可以在肿瘤细胞中复制并直接杀死肿瘤细胞,在所感染肿瘤细胞裂解后感染其周围肿瘤细胞;同时对正常人体细胞没有杀伤作用,具有意料之外的溶瘤效果。
Description
技术领域
本发明涉及基因治疗领域,特别涉及重组溶瘤腺病毒、用于制备重组溶瘤腺病毒的重组溶瘤腺病毒载体及其应用。
背景技术
癌症由自身因素(遗传基因突变,自然衰老等)或环境因素(如吸烟,紫外辐射,化学物质,病毒感染等)引起。根据WHO报道,肿瘤目前已经是继心血管疾病的世界第二大死因,全球有近1/6的死亡是由癌症造成的。2018年全球癌症死亡人数达960万。预计到2025年,全球每年新增癌症病例数将高达2449万例。其中,肺癌的死亡人数最多,随后是结直肠癌,胃癌,肝癌和乳腺癌。
治疗癌症的经典方法主要是手术,化学疗法,和放射性疗法。手术切除效果有限,对转移癌细胞没有作用;放疗和化疗副作用大,尽管靶点药物在很大程度上改善了患者生活质量,但耐受性是化疗一直面临的一个难题。近年来,免疫疗法已成为癌症治疗领域的热点。免疫疗法的原理是通过激活机体自身的免疫系统来消灭肿瘤细胞,具有疗效好,副作用小和防止复发等优点。
近几年溶瘤病毒在癌症治疗领域又重新兴起。溶瘤病毒(oncolytic virus),是一类具有复制能力,能够直接裂解肿瘤细胞的病毒。早在1912年,意大利医生就发现一名子宫颈癌患者在感染狂犬病病毒后肿瘤随之消退。2005年中国批准了世界上第一个溶瘤腺病毒(H101)上市,但临床疗效目前还未得到国际认可。该病毒敲除了E1B-55K和E3区大部分基因。E1B-55K蛋白能够抑制抗癌基因p53的表达,阻止P53介导的感染细胞的凋亡。由于正常的细胞中的P53蛋白功能完好,而大部分肿瘤丧失P53功能,因此,E1B-55K基因的删除使病毒能特异性在缺乏有功能的p53的肿瘤细胞内复制。然而,E1B-55K蛋白是病毒mRNA从细胞核输出必需的蛋白,因此,H101复制能力和溶瘤能力比野生毒株明显减弱。2015年,FDA批准了第一个溶瘤病毒疗法T-vec(单纯疱疹病毒-1)用于治疗手术切除后复发的黑色素瘤。作为第三代溶瘤病毒,T-vec删除了γ34.5基因,使其具有肿瘤细胞靶向性,同时它还携带了GM-CSF(粒细胞-巨噬细胞集落因子)增强抗肿瘤免疫能力。
溶瘤病毒是免疫疗法的一个重要分支,其可以通过多种不同的作用途径杀伤肿瘤细胞,并破坏肿瘤免疫抑制的微环境诱导长期的肿瘤特异性免疫反应,同时还可以通过携带治疗基因使其在肿瘤细胞中特异地,长时间地表达,从而增强抗肿瘤疗效。另外,溶瘤病毒与其他抗癌药物的联合用药的实验结果如联合免疫检查点抑制剂等方面都显现出良好的抗肿瘤效果。近年来,许多病毒包括痘苗病毒、呼肠孤病毒、麻疹病毒、单纯疱疹病毒、新城疫病毒以及柯萨奇病毒已经作为溶瘤剂进行了临床试验。
腺病毒(adenovirus)是一种没有包膜的直径为70~90nm的颗粒,由252个壳粒呈廿面体排列构成。每个壳粒的直径为7~9nm。衣壳里是线状双链DNA分子,约含4.7kb,两端各有长约100~600bp的反向末端重复序列。人腺病毒(Human adenoviruses,HAdV)属于腺病毒科(Adenoviridae),根据免疫学、生物学、生物化学特性不同,将其分为A~G7个亚种,共有52个血清型,不同的血清型有不同的器官亲和性并引起相应的临床表现。腺病毒侵入宿主细胞后至少能引起3种感染:慢性、潜伏性感染:常在淋巴细胞内发生,潜伏感染时外放的病毒量极少,细胞坏死也不明显,故临床上感染不明显,潜伏感染的机制尚不清楚。溶解性感染:病毒在细胞内如人类上皮细胞中经历复制过程,通过溶解细胞作用使细胞死亡。肿瘤样变异:此时病毒繁殖只进行最初几步,然后腺病毒DNA与细胞DNA整合并复制,但不产生感染性病毒,腺病毒抗原性较稳定。
周立,何婉婉,朱桢楠,et al.溶瘤腺病毒靶向癌症治疗的临床研究进展[J].中国生物工程杂志,2013,33(12):105-113.指出,溶瘤腺病毒能够特异性地感染肿瘤细胞并在肿瘤细胞中完成感染-复制周期,从而特异性地杀伤和裂解肿瘤细胞但不损伤其他正常细胞和组织,因此成为目前最具研究前景的抗肿瘤药物之一。不同的病毒有着复杂的生物学特性,而目前人类完全熟悉的病毒资源仍旧比较匮乏。尤其大多临床前实验资料均是来自免疫缺陷动物体内人肿瘤移植模型,与人在体内环境、组织细胞的生物学特性等方面都存在很大差异。已有的溶瘤腺病毒之间并无明显的共性,难以基于腺病毒的序列确定其是否具有溶瘤效果,但大多数腺病毒对肿瘤细胞不敏感,不具有溶瘤的特性。
发明内容
本发明的目的在于克服现有技术中的至少一种不足,提供一种溶瘤腺病毒载体及其应用。
本发明所采取的技术方案是:
本发明的第一个方面,提供:
一种复制型人腺病毒,其全序列如SEQ ID NO.:21所示,其中的抗性筛选基因可使用公知的筛选基因替换。
在一些实例中,所述复制型人腺病毒的全序列如SEQ ID NO.:21所示。
在一些实例中,所述病毒的E1区和E3区被删除。
在一些实例中,所述病毒可在动物细胞、人源细胞或人体内复制。
在一些实例中,所述复制型人腺病毒的构建方法包括:
S1)PCR扩增获得NBOV1901基因组的左右两端,连接在抗性载体质粒A得到pT-NBOV1901(L+R),线性化后与NBOV1901基因组重组得到基因组质粒pNBOV1901;
S2)PCR扩增获得从SrfI至整个E3区左右臂连接至抗性载体质粒B上,线性化后与PacI酶切的NBOV1901进行重组,得到去除SrfI至整个E3区的基因组质粒pNBOV1901△E3-SrfI;
S3)以NBOV1901基因组为模板,PCR扩增获得E3gp19K上游片段:SrfI至E3gp19K,和E3gp19K下游片段:E3gp19K至E3区包含E3-14.7K基因片段,将E3gp19K上游片段、E3gp19K下游片段和酶切后的构建载体三个片段重组连接至pNBOV1901△E3-SrfI左右臂之间,线性化后与pNBOV1901△E3-SrfI进行重组,得到修改了SrfI酶切位点的基因组质粒pNBOV1901△E3gp19K;
S4)PCR扩增获得E1区左右臂连接至抗性载体质粒B上,线性化后与SrfI酶切的pNBOV1901△E3gp19K重组,得到去除E1区的基因组质粒pNBOV1901△E3gp19K△E1;
S5)PCR扩增获得去除E1b19K、pRB基因的E1区基因组,连接至含有E1区左右臂的抗性载体质粒B上,线性化后与酶切后的pNBOV1901△E3gp19K△E1进行重组,得到敲除E1b19K、pRB基因的基因组质粒pNBOV1910,即所述复制型人腺病毒。
在一些实例中,抗性载体质粒A和抗性载体质粒B具有不同的抗性。
在一些实例中,抗性载体质粒A和抗性载体质粒B独立选自氨苄抗性载体质粒或卡那霉素抗性载体质粒。这些抗性质粒更为成熟,易于获得,同时筛选成本也更低。
在一些实例中,包括:
S1)PCR扩增获得NBOV1901基因组的左右两端,连接在氨苄抗性载体质粒得到pT-NBOV1901(L+R),线性化后与NBOV1901基因组重组得到基因组质粒pNBOV1901;
S2)PCR扩增获得从SrfI至整个E3区左右臂,连接至卡那霉素抗性载体质粒上,线性化后与PacI酶切的NBOV1901进行重组,得到去除SrfI至整个E3区的基因组质粒pNBOV1901△E3-SrfI;
S3)以NBOV1901基因组为模板,PCR扩增获得E3gp19K上游片段:SrfI至E3gp19K,和E3gp19K下游片段:E3gp19K至E3区包含E3-14.7K基因片段,将E3gp19K上游片段、E3gp19K下游片段和酶切后的构建载体三个片段重组连接至pNBOV1901△E3-SrfI左右臂之间,线性化后与pNBOV1901△E3-SrfI进行重组,得到修改了SrfI酶切位点的基因组质粒pNBOV1901△E3gp19K;
S4)PCR扩增获得E1区左右臂,连接至卡那霉素抗性载体质粒上,线性化后与SrfI酶切的pNBOV1901△E3gp19K重组,得到去除E1区的基因组质粒pNBOV1901△E3gp19K△E1;
S5)PCR扩增获得去除E1b19K、pRB基因的E1区基因组,连接至含有E1区左右臂的卡那霉素抗性载体质粒上,线性化后与酶切后的pNBOV1901△E3gp19K△E1进行重组,得到敲除E1b19K、pRB基因的基因组质粒pNBOV1910。
本发明的第二个方面,提供:
本发明第一个方面所述复制型人腺病毒作为重组溶瘤病毒载体的应用。
在一些实例中,所述重组溶瘤病毒载体负载有表达以下分子的核酸序列:
对肿瘤具有治疗效果的分子;
生物学报告示踪分子。
在一些实例中,所述对肿瘤具有治疗效果的分子选自肿瘤抑制因子、肿瘤杀伤因子、肿瘤微环境调节因子、肿瘤细胞表面特异性结合因子;
所述生物学报告示踪分子选自β-半乳糖苷酶、分泌型碱性磷酸酶、绿色荧光蛋白、荧光素酶。
在一些实例中,所述重组溶瘤病毒载体还负载有表达肿瘤特异性识别因子的核酸序列。
在一些实例中,所述肿瘤特异性识别因子选自肿瘤表位特异性识别因子、肿瘤细胞选择性复制因子。
这些分子或序列可是本领域技术人员已知的。
在一些实例中,所述肿瘤选自肺癌、肝癌,胃癌、结直肠癌、胰腺癌、卵巢癌。
在一些实例中,所述载体的原E1区和E3区的至少一个区域用于整合外源基因。
本发明的第三个方面,提供:
一种组合物,该组合物中含有本发明第一个方面所述的复制型人腺病毒。
在一些实例中,所述组合物中包括:a)免疫调控剂;b)免疫调控细胞;c)放射性治疗物;d)光疗法化合物;或e)化学治疗化合物中的至少一种。
在一些实例中,述组合物中还含有药学上可接受的佐剂、稀释剂或赋形剂。
本发明的第四个方面,提供:
一种溶瘤制剂,包括本发明第一个方面所述的复制型人腺病毒。
在一些实例中,所述复制型人腺病毒负载有表达以下分子的核酸序列:
对肿瘤具有治疗效果的分子;
生物学报告示踪分子。
在一些实例中,所述对肿瘤具有治疗效果的分子选自肿瘤抑制因子、肿瘤杀伤因子、肿瘤微环境调节因子、肿瘤细胞表面特异性结合因子;
所述生物学报告示踪分子选自β-半乳糖苷酶、分泌型碱性磷酸酶、绿色荧光蛋白、荧光素酶。
在一些实例中,所述重组溶瘤病毒载体还负载有表达肿瘤特异性识别因子的核酸序列。
在一些实例中,所述肿瘤特异性识别因子选自肿瘤表位特异性识别因子、肿瘤细胞选择性复制因子。
在一些实例中,所述肿瘤选自肺癌、肝癌,胃癌、结直肠癌、胰腺癌、卵巢癌。
本发明的第五个方面,提供:
组合物在制备预防或治疗肿瘤或肿瘤检测制剂中的应用,所述组合物如本发明第三个方面所述。
在一些实例中,所述肿瘤选自乳腺癌、脑癌、肺癌、鼻咽癌、头颈癌、肾癌、膀胱癌、肝癌、食道癌、胃癌、结直肠癌、胰腺癌、卵巢癌、皮肤癌、前列腺癌、输卵管癌、尿道癌、泌尿生殖系统癌、子宫内膜异位症、宫颈癌、骨癌或癌症的转移性病变。
本发明的有益效果是:
本发明一些实例所述的复制型人腺病毒,在负载相关核酸序列后,可以直接注射于实体肿瘤,包括但不限于H1299,还包括Skov-3、U251等肿瘤后,经鉴定,该腺病毒不仅可以在肿瘤细胞中复制并直接杀死肿瘤细胞,在所感染肿瘤细胞裂解后感染其周围肿瘤细胞;同时对正常人体细胞没有杀伤作用,具有意料之外的溶瘤效果。
本发明一些实例所述的复制型人腺病毒对于多种肿瘤细胞H1299、U251、Skov-3等具有双重靶向性。
附图说明
图1是利用同源重组对NBOV1901的基因组环化的原理(A),及pNBOV1901的酶切鉴定结果(B);
图2是敲除NBOV1901从SrfI至整个E3区基因组原理图(A),及pNBOV1901△E3-SrfI的PCR和酶切鉴定结果(B);
图3是敲除NBOV1901E3gp19K基因原理图(A)及pNBOV1901△E3gp19K酶切结果(B);
图4是敲除NBOV1901E1基因原理图(A)及pNBOV1901△E3gp19K的PCR及酶切鉴定结果(B);
图5是敲除NBOV1901E1B19K、pRB基因原理图(A)及pNBOV1910酶切结果(B);
图6是复制型腺病毒NBOV1901重组腺病毒的生产及纯化结果;
图7是复制型腺病毒NBOV1901重组腺病毒在各种肿瘤细胞双向筛选结果;
图8是复制型腺病毒NBOV1901重组腺病毒非核心区域改造对H1299细胞溶瘤效果影响;
图9是复制型腺病毒NBOV1901重组腺病毒在H1299小鼠肿瘤模型上的实验结果;
图10是现有溶瘤腺病毒的溶瘤作用。
图1~5中,M代表15000bp DNA Marker。
具体实施方式
本发明的新型腺病毒载体pNBOV1901改造自从人的咽拭子样品中分离到的一株腺病毒NBOV1901(全序列的GenBank:MH558113.1)。NBOV1901不同于目前已报道的腺病毒,为一种新型人腺病毒。腺病毒的E1A基因是病毒调节细胞周期的必需基因,通过E1A基因上CR2结合位点与细胞的Rb蛋白结合,使细胞周期由G1期进入S期。本发明的肿瘤靶向性腺病毒载体pNBOV1910,删除了E1A-CR2,使得该病毒的E1A不能与宿主细胞的Rb蛋白结合。因此,pNBOV1910只能选择性地在处于分裂期的细胞如肿瘤细胞中复制而不在正常细胞中复制,从而增加溶瘤的特异性和安全性。
腺病毒的E1B19K与细胞Bcl-2基因同源,可以通过与Beclin-1结合,抑制细胞凋亡。而E3gp19K蛋白可以在内质网上与MHC I类分子的重链结合阻止其转运到细胞表面,并且可以延缓MHC I的表达。因此,删除这两个基因能够提高病毒的肿瘤选择性及在肿瘤中的扩散能力,并激活宿主免疫反应,从而增强疫毒对肿瘤细胞的杀伤能力。
本腺病毒转录单位编码一系列具有相关功能的多肽,E1A单元编码两种主要蛋白质,它们激活转录并诱导宿主细胞进入细胞周期的S期;E1B编码两种阻断细胞凋亡的蛋白质;E2编码三种直接参与DNA复制的蛋白质;E3编码调节宿主对感染的反应的产物;较晚的mRNAs家族与衣壳成分的生产和组装有关。E4产物介导转录、RNA剪接和翻译调节;mRNA核输出并调节DNA复制和凋亡。E1B19K和E3的删除不会影响腺病毒的复制并且可以为外源基因的插入腾出空间
一种复制型腺病毒载体pNBOV1901,由如下方法制备得到:将NBOV1901基因组环化,敲除E3gp19K、E1b19K、pRB基因得到。
在一些实例中,在腺病毒质粒中引入编码RGD肽的基因,构成靶向性骨架质粒。
一种复制型人NBOV1901型溶瘤腺病毒载体制备方法,包含如下步骤:
S1)PCR扩增获得NBOV1901基因组的左右两端,连接在氨苄抗性载体质粒得到pT-NBOV1901(L+R),线性化后与NBOV1901基因组重组得到基因组质粒pNBOV1901;
S2)PCR扩增获得从SrfI至整个E3区左右臂,连接至卡那霉素抗性载体质粒上,线性化后与PacI酶切的NBOV1901进行重组,得到去除SrfI至整个E3区的基因组质粒pNBOV1901△E3-SrfI;
S3)以NBOV1901基因组为模板,PCR扩增获得E3gp19K上游片段:SrfI至E3gp19K,和E3gp19K下游片段:E3gp19K至E3区包含E3-14.7K基因片段,将E3gp19K上游片段、E3gp19K下游片段和酶切后的构建载体三个片段重组连接至pNBOV1901△E3-SrfI左右臂之间,线性化后与pNBOV1901△E3-SrfI进行重组,得到修改了SrfI酶切位点的基因组质粒pNBOV1901△E3gp19K;
S4)PCR扩增获得E1区左右臂,连接至卡那霉素抗性载体质粒上,线性化后与SrfI酶切的pNBOV1901△E3gp19K重组,得到去除E1区的基因组质粒pNBOV1901△E3gp19K△E1;
S5)PCR扩增获得去除E1b19K、pRB基因的E1区基因组,连接至含有E1区左右臂的卡那霉素抗性载体质粒上,线性化后与酶切后的pNBOV1901△E3gp19K△E1进行重组,得到敲除E1b19K、pRB基因的基因组质粒pNBOV1910。
氨苄抗性载体质粒、卡那霉素抗性载体质粒也可以使用其他周知的筛选质粒替换,只要可以实现产物的有效分离即可。
在一些实例中,步骤S1的具体方法为:
以NBOV1901基因组为模板,PCR扩增得到NBOV1901基因组左右两端L-NBOV1901和R-NBOV1901作为重组臂连接到线性化的T载体上,得到pT-NBOV1901(L+R),同时在pT-NBOV1901(L+R)的左右臂之间引入了EcoRI、BamHI作为酶切位点,EcoRI+BamHI双酶切pT-NBOV1901(L+R)线性化后与NBOV1901基因组重组,得到pNBOV1901。
进一步的,在一些实例中,步骤S1的具体方法为:
以NBOV1901基因组为模板,PCR扩增得到NBOV1901基因组左右两端L-NBOV1901和R-NBOV1901,使用Exnase重组酶将L-NBOV1901和R-NBOV1901和线性化的T载体进行三片段重组得到pT-NBOV1901(L+R),同时在pT-NBOV1901(L+R)的左右臂之间引入了EcoRI、BamHI作为酶切位点,pT-NBOV1901(L+R)用EcoRI+BamHI双酶切线性化后与NBOV1901基因组重组,得到pNBOV1901。
在一些实例中,步骤S2的具体方法为:
以NBOV1901基因组为模板,PCR扩增获得从SrfI至整个E3区左右臂基因L-ΔE3-SrfI及R-ΔE3-SrfI,连接到线性化的T载体上,得到pT-ΔE3-SrfI(L+R),线性化后与经过PacI酶切的pNBOV1901基因组进行重组,得到敲除ΔE3-SrfI同时在ΔE3-SrfI位置引入唯一的酶切位点PacI的基因组质粒pNBOV1901△E3-SrfI。
进一步的,在一些实例中,步骤S2的具体方法为:
以NBOV1901基因组为模板,PCR扩增获得E3-SrfI区左右两端同源臂L-△E3-SrfI和R-△E3-SrfI,使用Exnase重组酶进行三片段连接得到pVax-△E3-SrfI。线性化后与PacI酶切线性化的pNBOV1901同源重组,经氨苄抗性筛选后得到敲除E3-SrfI区基因同时引入唯一的线性化酶切位点swaI的质粒pNBOV1901△E3-SrfI。
在一些实例中,步骤S3的具体方法为:
以NBOV1901基因组为模板,PCR扩增获得E3gp19K上游片段(SrfI至E3gp19K)和E3gp19K下游片段(E3gp19K至E3区,包含E3-14.7K基因片段),Exnase重组酶三片段重组连接到pVAX-ΔE3-SrfI(L+R)左右臂之间,得到pVAX-ΔE3gp19K载体质粒,线性化后与PacI酶切的pNBOV1901△E3-SrfI基因组质粒进行同源重组,经氨苄抗性基因筛选得到敲除E3gp19K的pNBOV1901△E3gp19K基因组质粒。
在一些实例中,步骤S4的具体方法为:
以NBOV1901基因组为模板,PCR扩增得到E1基因同源重组臂L-ΔE1及R-ΔE1,连接到线性化的T载体上,得到pVAX-ΔE1(L+R),线性化后与SrfI酶切的pNBOV1901ΔE3gp19K同源重组,经氨苄抗性筛选得到敲除E1基因并在E1基因区引入唯一的线性化酶切位点SrfI的质粒pNBOV1901△E3gp19K△E1。
进一步的,在一些实例中,步骤S4的具体方法为:
以NBOV1901基因组为模板,PCR扩增得到E1基因同源重组臂L-ΔE1及R-ΔE1和以pVAX载体为模板PCR获得pVAX的骨架使用Exnase重组酶进行三片段连接得到pVAX-△E3gp19K△E1(L+R),pVAX-△E3gp19K△E1(L+R)使用Bstz17I+SgrAI双酶切,pNBOV1901ΔE3gp19K使用SrfI进行酶切进行线性化,将两者酶切回收的片段进行同源重组得到敲除E1基因同时引入唯一酶切位点SrfI的基因组质粒pNBOV1901△E3gp19K△E1。
在一些实例中,步骤S5的具体方法为:
以NBOV1901基因组为模板,PCR扩增获得缺失E1b19K、pRB基因的E1区基因,连接到pVAX-△E3gp19K△E1(L+R)左右臂之间,线性化后与SrfI酶切的pNBOV1901△E3gp19K△E1基因组进行同源重组,经氨苄抗性基因筛选得到敲除E1b19K、pRB基因的基因组质粒pNBOV1910。
进一步的,在一些实例中,步骤S5的具体方法为:
以NBOV1901基因组为模板,PCR扩增获得缺失E1b19K、pRB基因的E1区基因并与SrfI酶切线性化的pVAX-△E3gp19K△E1(L+R)使用Exnase重组酶进行重组得到pVAX-△E1B19K_pRB,pVAX-△E1B19K_pRB使用Bstz17I+SgrAI双酶切,pNBOV1901ΔE3gp19KΔE1使用SrfI进行酶切进行线性化,将两者酶切回收的片段进行同源重组经氨苄抗性基因筛选得到缺失E1b19K、pRB基因的基因组质粒pNBOV1910。
在一些实例中,所述重组腺病毒载体pNBOV1910使用AsisI酶切进行线性化,乙醇沉淀回收后转染293细胞进行病毒拯救、扩增培养,以CsCl密度梯度离心法纯化得到NBOV1910。
本发明术语“外源序列”是指非NBOV1901型腺病毒来源的任何DNA序列。本领域普通技术人员应当理解,外源序列可以是外源基因表达框,也可以是shRNA或miRNA的表达框等。
在以下实施例中,根据本领域技术人员的理解,外源基因表达框可包含真核启动子、外源基因编码序列、转录终止子。所述外源基因编码序列可以是但不仅限于绿色荧光蛋白、其他病毒抗原、shRNA等的编码序列。
为了能够更清楚地理解本发明的技术内容,特举以下实施例结合附图详细说明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法,通常按照常规条件,例如Sambrook等人,分子克隆:实验室手册(NewYork:ColdSpring Harbor Laboratory Press,1989)中所述的条件,或按照制造厂商所建议的条件。实施例中所用到的各种常用化学试剂,均为市售产品。
除非另有定义,本发明所使用的所有的技术和科学术语与属于本发明的技术领域的技术人员通常理解的含义相同。本发明的说明书中所使用的术语只是为了描述具体的实施例的目的,不用于限制本发明。
实施例1:NBOV1901基因组的环化
1.构建环化NBOV1901基因组的穿梭质粒pT-NBOV1901(L+R)。
参照图1A,以NBOV1901的基因组为模板,PCR获得NBOV1901基因组的左臂(L-NBOV1901)和右臂(R-NBOV1901)。
L-NBOV1901引物:
L-NBOV1901-F:gcgggatccgaattcttaatgcgatcgccatcatcaataatataccttat(SEQID NO.:1)
L-NBOV1901-R:tatctgcatgagcatgatgatatcctttgacccggaacgcgg(SEQ ID NO.:2)
PCR条件:95℃,3min;95℃,30s;60℃30s;72℃,30s;cycles 28;72℃,5min;12℃保存。
R-NBOV1901引物:
R-NBOV1901-F:ccgcgttccgggtcaaaggatatcatcatgctcatgcagata(SEQ ID NO.:3)
R-NBOV1901-R:gaagcgagatcgaattcttagcgatcgccatcatcaataaatacctta(SEQ IDNO.:4)
PCR条件:95℃,3min;95℃,30s;60℃30s;72℃,1min;cycles 28;72℃,5min;12℃保存。
2.构建pNBOV1901。
pT-NBOV1901(L+R)使用EcoRI+BamHI进行酶切线性化,然后和NBOV1901的基因组共转化BJ5183感受态细胞进行重组,氨苄抗性平板进行抗性筛选,将筛选得到单克隆扩增后提取其质粒转化XL感受态细胞,提取质粒得到pNBOV1901,使用不同的酶切方式进行鉴定(图1B),pNBOV1901在基因组的两侧引入了两个AsisI酶切位点,方便后续对改造后的NBOV1901的基因组进行线性化进行病毒拯救。
实施例2:SrfI至E3区基因的敲除,构建pNBOV1901ΔE3_SrfI质粒的构建
1.构建SrfI至E3区基因敲除的穿梭质粒pVax-ΔE3_SrfI(L+R)。
参照图2A,以NBOV1901的基因组为模板,PCR获得SrfI至E3区基因的左臂(L-ΔE3_SrfI)和右臂(R-ΔE3_SrfI)。
L-ΔE3_SrfI引物:
L-ΔE3_SrfI-F:gatatacgcgtgtatac cttcccaggatggcaccca(SEQ ID NO.:5)
L-ΔE3_SrfI-R:gtaagtaatttattgtgtgtttatg ttaattaa ctgtgtgaccgctgctgt(SEQ ID NO.:6)
PCR条件:95℃,3min;95℃,30s;60℃30s;72℃,30s;cycles 28;72℃,5min;12℃保存。
R-ΔE3引物:
R-ΔE3_SrfI-F:acagcagcggtcacacag ttaattaa cataaacacacaataaattacttac(SEQ ID NO.:7)
R-ΔE3_SrfI-R:ccgcccagtagaagcgccggtg ccgcccgttttaatttccatgtt(SEQ IDNO.:8)
PCR条件:95℃,3min;95℃,30s;60℃30s;72℃,50s;cycles 28;72℃,5min;12℃保存。
L-ΔE3_SrfI、R-ΔE3_SrfI和Bstz17I+SgrAI双酶切pVax载体获得的质粒骨架使用Exnase酶进行三片段连接得到pVax-ΔE3_SrfI(L+R)。
2.构建pNBOV1901ΔE3_SrfI
pVax-ΔE3_SrfI(L+R)使用Bstz17I+SgrAI双酶切,pNBOV1901使用PacI进行酶切,将两者酶切回收的片段共转化BJ5183感受态细胞进行重组,用氨苄抗性平板进行抗性筛选,将筛选得到单克隆扩增后提取其质粒转化XL感受态细胞,提取质粒得到pNBOV1901ΔE3_SrfI,使用不同的酶切方式进行鉴定(图2B),pNBOV1901ΔE3_SrfI在敲除基因区引入唯一酶切位点PacI,方便后续克隆操作。
实施例3:构建pNBOV1901ΔE3gp19K质粒
1.构建敲除E3gp19K的穿梭载体pVAX-△E3gp19K。
参照图3A,以NBOV1901基因组为模板,PCR扩增获得除E3gp19K外从SrfI(位点)至整个E3区基因片段。
E3gp19K上游片段P1-E3-SrfI△E3gp19K:
E3gp19K-F1:gtcacagggtgcggtcgccaggacagggtataactcacct(SEQ ID NO.:9)
E3gp19K-R1:ggaatacaagcaagcggaaaa tcatcttggatgtcgcccccag(SEQ ID NO.:10)
PCR条件:95℃,3min;95℃,30s;60℃30s;72℃,30s;cycles 28;72℃,5min;12℃保存。
E3gp19K下游片段P2-E3-SrfI△E3gp19K;
E3gp19K-F2:ctgggggcgacatccaagatga ttttccgcttgcttgtattcc(SEQ ID NO.:11)
E3gp19K-R2:ccgcccagtagaagcgccggtg ccgcccgttttaatttccatgtt(SEQ ID NO.:8)
P1-E3-SrfI△E3gp19K、P2-E3-SrfI△E3gp19K和PacI酶切后的pVAX-△E3-SrfI(L+R)使用Exnase酶进行三片段连接得到pVAX-△E3gp19K。
2.构建pNBOV1901ΔE3gp19K质粒
pVAX-△E3gp19K使用Bstz17I+SgrAI双酶切,pNBOV1901ΔE3_SrfI使用PacI进行酶切,将两者酶切回收的片段共转化BJ5183感受态细胞进行重组,用氨苄抗性平板进行抗性筛选,将筛选得到单克隆扩增后提取其质粒转化XL感受态细胞,提取质粒得到pVAX-△E3gp19K,使用不同的酶切方式进行鉴定(图3B)。
实施例4:构建pNBOV1901△E3gp19K△E1质粒
1.构建敲除E1区基因的穿梭载体pVAX-△E3gp19K△E1(L+R)。
参照图4A,以NBOV1901基因组为模板,PCR扩增得到E1基因同源重组臂L-ΔE1及R-ΔE1。
L-ΔE1引物:
L-ΔE1-FW:cagatatacgcgtgtataccatcatcaataatatacct(SEQ ID NO.:12)
L-ΔE1-RW:agacagcaagacacttgctatcgatttttagtcccggtgttgga(SEQ ID NO.:13)
PCR条件:95℃,3min;95℃,30s;60℃30s;72℃,30s;cycles 28;72℃,5min;12℃保存。
R-ΔE1引物:
R-ΔE1-FW:tccaacaccgggactaaaaatcgatagcaagtgtcttgctgtct(SEQ ID NO.:14)
R-ΔE1-RW:gcccagtagaagcgccggtggaattcatctgaactcaaagcgtg(SEQ ID NO.:15)
PCR条件:95℃,3min;95℃,30s;60℃30s;72℃,30s;cycles 28;72℃,5min;12℃保存。
M-ΔE1、R-ΔE1和Bstz17I+SgrAI双酶切pVax载体获得的质粒骨架使用Exnase酶进行三片段连接得到pVAX-△E3gp19K△E1(L+R)。
2.构建pNBOV1901△E3gp19K△E1。
pVAX-△E3gp19K△E1(L+R)使用Bstz17I+SgrAI双酶切,p NBOV1901ΔE3gp19K使用SrfI进行酶切,将两者酶切回收的片段共转化BJ5183感受态细胞进行重组,用氨苄抗性平板进行抗性筛选,将筛选得到单克隆扩增后提取其质粒转化XL感受态细胞,提取质粒得到pNBOV1901△E3gp19K△E1,使用不同的酶切方式进行鉴定(图4B),pNBOV1901△E3gp19K△E1在敲除基因区引入唯一酶切位点SrfI,方便后续克隆操作。
实施例5:构建载体pNBOV1901△E3gp19K△E1B19K_pRB,即pNBOV1910
1.构建敲除E1B19K、pRB基因的穿梭载体穿梭载体pVAX-△E1B19K_pRB。
参照图5A,以NBOV1901基因组为模板,PCR扩增获得缺失E1b19K、pRB基因的E1区基因。
P1-△E1B19K_pRB引物:
P1-△E1B19K_pRB-FW:caacaccgggactaaaaatgagacatattatctgcc(SEQ ID NO.:16)
P1-△E1B19K_pRB-RW:atcctcgtcgtcactgggtgg atcgaccacctccggtacaa(SEQ IDNO.:17)
PCR条件:95℃,3min;95℃,30s;60℃30s;72℃,30s;cycles 28;72℃,5min;12℃保存。
P2-△E1B19K_pRB引物:
P2-△E1B19K_pRB-FW:ttgtaccggaggtggtcgat ccacccagtgacgacgaggat(SEQ IDNO.:18)
P2-△E1B19K_pRB-RW:gatgggtttcttcgctccat gaggtcaaatgtaaccaaga(SEQ IDNO.:19)
PCR条件:95℃,3min;95℃,30s;60℃30s;72℃,30s;cycles 28;72℃,5min;12℃保存。
P3-△E1B19K_pRB引物:
P3-△E1B19K_pRB-FW:tcttggttacatttgacctc atggagcgaagaaacccatc(SEQ IDNO.:20)
P3-△E1B19K_pRB-RW:tcttggttacatttgacctc atggagcgaagaaacccatc(SEQ IDNO.:20)
PCR条件:95℃,3min;95℃,30s;60℃30s;72℃,30s;cycles 28;72℃,5min;12℃保存。
P1-△E1B19K_pRB、P2-△E1B19K_pRB、P3-△E1B19K_pRB和SrfI酶切后的pVAX-△E1(L+R)使用Exnase酶进行四片段连接得到pVAX-△E1B19K_pRB。
2.构建pNBOV1901△E3gp19K△E1B19K_pRB
pVAX-△E1B19K_pRB使用Bstz17I+SgrAI双酶切,pNBOV1901ΔE3gp19KΔE1使用SrfI进行酶切,将两者酶切回收的片段共转化BJ5183感受态细胞进行重组,用氨苄抗性平板进行抗性筛选,将筛选得到单克隆扩增后提取其质粒转化XL感受态细胞,提取质粒得到pNBOV1910,使用不同的酶切方式进行鉴定(图5B)。
经测序,pNBOV1910如SEQ ID NO.:21所示。
实施例6:复制型腺病毒NBOV1901重组腺病毒的生产及纯化结果
pNBOV1910用AsisI线性化后进行病毒拯救,拯救出毒以后逐步扩大培养,在对毒种进行PCR和酶切鉴定确认后进行大扩培养,收集细胞,CsCl密度梯度离心纯化病毒,结果如图6所示,收集得到的病毒,-80度保存。从图中可以看出,pNBOV1910保留了复制型腺病毒NBOV1901生产性能,复制能力未有减弱。
实施例7:不同剂量NBOV1910、NBOV1901在H1299等肿瘤细胞溶瘤效果
对数生长期的各肿瘤细胞铺板5*10^3cell/well,培养24h,每孔病毒量TCID50分 别为1250、250、50、10、2、0梯度进行病毒稀释,稀释后每孔添加100μl感染细胞孵育1h,培养24-72小时(72hpi)或96hpi测定肿瘤细胞杀伤效果。
实验结果如图7所示。接毒72h后CCK-8检测结果,结果显示随着病毒浓度的增加对肿瘤细胞杀伤作用更强。改造得到的NBOV1910具有良好的溶瘤效果,在某些剂量区间具有更好的溶瘤效果。
实施例8:不同剂量NBOV1901ΔE3ΔE1B19K_pRb、NBOV1910、NBOV1901在H1299肿瘤细胞溶瘤效果
对数生长期的各肿瘤细胞铺板5×10^3cell/well,培养24h,每孔病毒量TCID50分 别为1250、250、50、10、2、0梯度进行病毒稀释,稀释后每孔添加100μl感染细胞孵育1h,培养72小时(72hpi)或96hpi测定肿瘤细胞杀伤效果。
图8为接毒72h后CCK-8检测结果,结果显示复制型溶瘤腺病毒NBOV1901可变区的改造不影响其溶瘤效果。
实施例9:NBOV1910、NBOV1901小鼠体内抗肿瘤效果
用Balb/c_nude小鼠模型,在5-6周龄的Balb/c_nude小鼠大腿与背腹部交界或前腿后肋下皮肤松弛处接种5×10^6cell的H1299细胞。当肿瘤生长到200mm3时,用1×1011VP病毒在瘤内注射分别注射PBS、NBOV1910和NBOV1901,然后观察肿瘤大小和肿瘤清除率。
实验结果如图9所示,说明治疗组NBOV1910、NBOV01能够显著抑制肿瘤生长,具有治疗肿瘤的潜力。
图10是现有溶瘤腺病毒的溶瘤作用(参见Taki M,Kagawa S,Nishizaki M,etal.Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405(‘Telomelysin-RGD’)[J].Oncogene,2005,24(19):3130-3140.),可见NBOV1910、NBOV1901在非小细胞肺癌细胞具有更好的效果。
SEQUENCE LISTING
<110> 广州恩宝生物医药科技有限公司
<120> 一种复制型人腺病毒及其应用
<130>
<160> 21
<170> PatentIn version 3.5
<210> 1
<211> 50
<212> DNA
<213> 人工引物
<400> 1
gcgggatccg aattcttaat gcgatcgcca tcatcaataa tataccttat 50
<210> 2
<211> 42
<212> DNA
<213> 人工引物
<400> 2
tatctgcatg agcatgatga tatcctttga cccggaacgc gg 42
<210> 3
<211> 42
<212> DNA
<213> 人工引物
<400> 3
ccgcgttccg ggtcaaagga tatcatcatg ctcatgcaga ta 42
<210> 4
<211> 48
<212> DNA
<213> 人工引物
<400> 4
gaagcgagat cgaattctta gcgatcgcca tcatcaataa atacctta 48
<210> 5
<211> 36
<212> DNA
<213> 人工引物
<400> 5
gatatacgcg tgtatacctt cccaggatgg caccca 36
<210> 6
<211> 51
<212> DNA
<213> 人工引物
<400> 6
gtaagtaatt tattgtgtgt ttatgttaat taactgtgtg accgctgctg t 51
<210> 7
<211> 51
<212> DNA
<213> 人工引物
<400> 7
acagcagcgg tcacacagtt aattaacata aacacacaat aaattactta c 51
<210> 8
<211> 45
<212> DNA
<213> 人工引物
<400> 8
ccgcccagta gaagcgccgg tgccgcccgt tttaatttcc atgtt 45
<210> 9
<211> 40
<212> DNA
<213> 人工引物
<400> 9
gtcacagggt gcggtcgcca ggacagggta taactcacct 40
<210> 10
<211> 43
<212> DNA
<213> 人工引物
<400> 10
ggaatacaag caagcggaaa atcatcttgg atgtcgcccc cag 43
<210> 11
<211> 43
<212> DNA
<213> 人工引物
<400> 11
ctgggggcga catccaagat gattttccgc ttgcttgtat tcc 43
<210> 12
<211> 38
<212> DNA
<213> 人工引物
<400> 12
cagatatacg cgtgtatacc atcatcaata atatacct 38
<210> 13
<211> 44
<212> DNA
<213> 人工引物
<400> 13
agacagcaag acacttgcta tcgattttta gtcccggtgt tgga 44
<210> 14
<211> 44
<212> DNA
<213> 人工引物
<400> 14
tccaacaccg ggactaaaaa tcgatagcaa gtgtcttgct gtct 44
<210> 15
<211> 44
<212> DNA
<213> 人工引物
<400> 15
gcccagtaga agcgccggtg gaattcatct gaactcaaag cgtg 44
<210> 16
<211> 36
<212> DNA
<213> 人工引物
<400> 16
caacaccggg actaaaaatg agacatatta tctgcc 36
<210> 17
<211> 41
<212> DNA
<213> 人工引物
<400> 17
atcctcgtcg tcactgggtg gatcgaccac ctccggtaca a 41
<210> 18
<211> 41
<212> DNA
<213> 人工引物
<400> 18
ttgtaccgga ggtggtcgat ccacccagtg acgacgagga t 41
<210> 19
<211> 40
<212> DNA
<213> 人工引物
<400> 19
gatgggtttc ttcgctccat gaggtcaaat gtaaccaaga 40
<210> 20
<211> 40
<212> DNA
<213> 人工引物
<400> 20
tcttggttac atttgacctc atggagcgaa gaaacccatc 40
<210> 21
<211> 32767
<212> DNA
<213> 腺病毒
<400> 21
catcatcaat aatatacctt attttggatt gaagccaata tgataatgag ggggtggagt 60
ttgtgacgtg gcgcggggcg tgggaacggg gcgggtgacg tagtagtgtg gcggaagtgt 120
gatgttgcaa gtgtggcgga acacatgtaa gcgacggatg tggtaaaagt gacgtttttg 180
gtgtgcgccg gtgtacacgg gaagtgacaa ttttcgcgcg gttttaggcg gatgttgtag 240
taaatttggg cgtaaccgag taagatttgg ccattttcgc gggaaaactg aataagagga 300
agtgaaatct gaataattct gtgttactca tagcgcgtaa tatttgtcta gggccgcggg 360
gactttgacc gtttacgtgg agactcgccc aggtgttttt ctcaggtgtt ttccgcgttc 420
cgggtcaaag ttggcgtttt attattatag tcagctgacg cgtagtgtat ttatacccgg 480
tgagttcctc aagaggccac tcttgagtgc cagcgagtag agttttctcc tccgagccgc 540
tccaacaccg ggactaaaaa tgagacatat tatctgccac ggaggtgtta ttaccgaaga 600
aatggccgcc agtcttttgg accagctgat cgaagaggta ctggctgata atcttccacc 660
tcctagccat tttgaaccac ctacccttca cgaactgtat gatttagacg tgacggcccc 720
cgaagatccc aacgaggagg cggtttcgca gatttttccc gactctgtaa tgttggcggt 780
gcaggaaggg attgacttac tcacttttcc gccggcgccc ggttctccgg agccgcctca 840
cctttcccgg cagcccgagc agccggagca gagagccttg ggtccggttt ctatgccaaa 900
ccttgtaccg gaggtggtcg atccacccag tgacgacgag gatgaagagg gtgaggagtt 960
tgtgttagat tatgtggagc agcccgggca cggttgcagg tcttgtcatt atcaccggag 1020
gaatacgggg gacccagata ttatgtgttc gctttgctat atgaggacct gtggcatgtt 1080
tgtctacagt aagtgaaatt atgggcagtg ggtgatagag tggtgggttt ggtgtggtaa 1140
tttttttttt aatttttgca gttttgtggt ttaaagaatt ttgtattgta attttttaaa 1200
aggtcctgtg tctgaacctg agcctgagcc cgagccagaa ccggagcctg caagacctac 1260
tcggcgtcct aaaatggtgc ctgctatcct gagacgcccg acatcacctg tgaccagaga 1320
atgcaatagt agtacggata gctgtgactc cggtccttct aacacacctc ctgagataca 1380
cccggtggtc ccgctgtgcc ccattaaacc agttgccgtg agagttggtg ggcgtcgcca 1440
ggctgtggaa tgtatcgagg acttgcttaa cgagcctggg caacctttgg acttgagctg 1500
taaacgcccc aggccataag gtgtaaacct gtgattgcgt gtgtggttaa cgcctttgtt 1560
tgctgaatga gttgatgtaa gtttaataaa aagggtgaga taatgtttaa cttgcatggc 1620
gtgttaaatg gggcggggct taaagggtat ataatgcgcc gtgggctaat cttggttaca 1680
tttgacctca tggagcgaag aaacccatct gagcgggggg tacctgctgg attttctggc 1740
catgcatctg tggagagcgg tggtgagaca caagaatcgc ctgctactgt tgtcttccgt 1800
ccgcccggca ataataccga cggaggagca gcagcagcag cagcagcagc aggaggaagc 1860
caggcggcgg cggcggcagg agcagagccc atggaacccg agagccggcc tggaccctcg 1920
ggaatgaatg ttgtacaggt ggctgaactg tttccagaac tgagacgcat tttaaccatt 1980
aacgaggatg ggcagggact aaagggggta aagagggagc ggggggcttc tgaggctata 2040
gaggaggcta ggaatctaac ttttagctta atgaccagac accgtcctga gtgtgttact 2100
tttcagcaga ttaaggataa ttgtgctaat gagcttgatc tgctggcgca gaagtattcc 2160
atagagcagc tgaccactta ctggctgcag ccaggggatg attttgagga ggctattagg 2220
gtatatgcaa aggtggcact taggccagat tgcaagtaca agattagcaa acttgtaaat 2280
atcaggaatt gttgctacat ttctgggaac ggggccgagg tggagataga tacggaggat 2340
agggtggcct ttagatgtag catgataaat atgtggccgg gggtgcttgg catggacggg 2400
gtggttttta tgaatgtgag gtttactggc cccaatttta gcggtacggt tttcctggcc 2460
aataccaacc ttatcctaca cggtgtaagc ttctatgggt ttaacaatac ctgcgtggaa 2520
gcctggaccg atgtaagggt tcggggctgt gccttttact tctgctggaa gggggtggtg 2580
tgtcgcccca aaagcagggc ttcaattaag aaatgcctct ttgaaaggtg taccttgggt 2640
atcctgtctg agggtaactc cagggtgcgc cacaatgtgg cctccgactg tggttgcttc 2700
atgctagtga aaagcgtggc tgtgattaag cataacatgg tgtgtggcaa ctgcgaggac 2760
agggcctctc agatgctgac ctgctcggac ggcaactgtc acctgctgaa gaccattcac 2820
gtagccagcc actctcgcaa ggcctggcca gtgtttgagc acaacatatt gacccgctgt 2880
tccttgcatt tgggtaacag gaggggggtg ttcctacctt accaatgcaa tttgagtcac 2940
actaagatat tgcttgagcc cgagagcatg tccaaggtga acctgaacgg ggtgtttgac 3000
atgaccatga agatctggaa ggtgctgagg tacgatgaga cccgcaccag gtgcagaccc 3060
tgcgagtgtg gcggtaaaca tattaggaac cagcctgtga tgctggatgt gaccgaggag 3120
ctgaggcccg atcacttggt gctggcctgc acccgcgctg agtttggctc tagcgatgaa 3180
gatacagatt gaggtactga aatgtgtggg cgtggcttaa gggtgggaaa gaatatataa 3240
ggtggggggt ctcatgtagt tttgtatctg ttttgcagca gccgccgcca tgagcaccaa 3300
ctcgtttgat ggaagcattg tgagctcata tttgacaaca cgcatgcccc catgggccgg 3360
ggtgcgtcag aatgtgatgg gctccagcat tgatggtcgc cccgtcctgc ccgcaaactc 3420
tactaccttg acctacgaga ccgtgtctgg aacgccgttg gagactgcag cctccgccgc 3480
cgcttcagcc gctgcagcca ccgcccgcgg gattgtgact gactttgctt tcctgagccc 3540
gcttgcaagc agtgcagctt cccgttcatc cgcccgcgat gacaagttga cgactctttt 3600
ggcacaattg gattctttga cccgggaact taatgtcgtt tctcagcagc tgttggagct 3660
gcgccagcag gtttctgccc tgaaggcttc ctcccctccc aatgcggttt aaaacataaa 3720
taaaaaccag actctgtttg gatttggatc aagcaagtgt cttgctgtct ttatttaggg 3780
gttttgcgcg cgcggtaggc ccgggaccag cggtctcggt cgttgagggt cctgtgtatt 3840
ttttccagga cgtggtagag gtggctctgg atgttcagat acatgggcat aagcccgtct 3900
ctggggtgga ggtagcacca ctgcagagct tcatgctgcg gggtggtgtt gtagatgatc 3960
cagtcgtagc aggagcgctg ggcgtggtgc ctaaaaatgt ccttcagaag caagctgatt 4020
gccaggggca ggcccttggt gtaagtgttt acaaagcggt taagctggga tgggtgcata 4080
cgtggggata tgagatgcat cttggactgt atttttaggt tggctatgtt cccagccata 4140
tccctcctgg gattcatgtt gtgcagaacc accagcacag tgtatccggt gcacttggga 4200
aatttgtcat gtagcttaga aggaaatgcg tggaagaact tggagacgcc cttgtgacct 4260
ccaagatttt ccatgcattc gtccataatg atggcaatgg gcccacgggc ggcggcctgg 4320
gcgaagatat ttctgggatc actaacgtca tagttgtgtt ccaggataag atcgtcatag 4380
gccattttta caaagcgcgg gcggagggtg ccagactgcg gtatgatggt tccatccggt 4440
ccaggggcgt agttaccctc acagatttgc atttcccacg ctttgagttc agatgggggg 4500
atcatgtcta cctgcggggc gatgaagaaa acggtttccg gggtagggga gatcagctgg 4560
gaagaaagca cgttcctgag cagctgcgac ttaccgcagc cggtgggccc gtaaatcaca 4620
cctattaccg gctgcaactg gtagttaaga gagctgcagc tgccgtcatc cctgagcagg 4680
ggggccactt cgttaagcat gtccctgact cgcatgtttt ccctgaccaa atccgccaga 4740
aggcgctcgc cgcccagcga tagcagttct tgcaaggaag caaagttttt caacggtttg 4800
aggccgtccg ccgtaggcat gcttttgagc gtttgaccaa gcagttccag gcggtcccac 4860
agctcggtca cgtgctctac ggcatctcga tccagcatat ctcctcgttt cgcgggttgg 4920
ggcggctttc gctgtacggc agtagtcggt gctcgtccag acgggccagg gtcatgtctt 4980
tccacgggcg cagggtcctc gtcagcgtag tctgggtcac ggtgaagggg tgcgctccgg 5040
gctgcgcgct ggccagggtg cgcttgaggc tggtcctgct ggtgctgaag cgctgccggt 5100
cttcgccctg cgcgtcggcc aggtagcatt tgaccatggt gtcatagtcc agcccctccg 5160
cggcgtggcc cttggcgcgc agcttgccct tggaggaggc gccgcacgag gggcagtgca 5220
gacttttgag ggcgtagagc ttgggcgcga gaaataccga ttccggggag taggcatccg 5280
cgccgcaggc cccgcagacg gtctcgcatt ccacgagcca ggtgagctct ggccgttcgg 5340
ggtcaaaaac caggtttccc ccatgctttt tgatgcgttt cttacctctg gtttccatga 5400
gccggtgtcc acgctcggtg acgaaaaggc tgtccgtgtc cccgtataca gacttgagag 5460
gcctgtcctc gagcggtgtt ccgcggtcct cctcgtatag aaactcggac cactctgaga 5520
cgaaggctcg cgtccaggcc agcacgaagg aggctaagtg ggaggggtag cggtcgttgt 5580
ccactagggg gtccactcgc tccagggtgt gaagacacat gtcgccctct tcggcatcaa 5640
ggaaggtgat tggtttgtag gtgtaggcca cgtgaccggg tgttcctgaa ggaggggtat 5700
aaaagggggt gggggcgcgt tcgtcctcac tctcttccgc atcgctgtct gcgagggcca 5760
gctgttgggg tgagtactcc ctctcaaaag cgggcatgac ttctgcgcta aggttgtcag 5820
tttccaaaaa cgaggaggat ttgatgttca cctggcccgc ggtgatgcct ttgagggtgg 5880
ccgcgtccat ctggtcagaa aagacaatct ttttgttgtc aagcttggtg gcaaacgacc 5940
cgtagagggc gttggacagc aacttggcaa tggagcgcag ggtttggttt ttgtcgcgat 6000
cggcacgctc cttggccgcg atgtttagct gcacgtattc acgcgcaacg caccgccatt 6060
cgggaaagac ggtggtgcgc tcgtcgggca ccaggcgcac gcgccaaccg cggttgtgca 6120
gggtgacaag gtcaacgctg gtggctacct ctccgcgtag gcgctcgttg gtccagcaga 6180
ggcggccgcc cttgcgcgag caaaatggcg gtagggggtc tagctgcgtc tcgtctgggg 6240
ggtccgcgtc cacggtaaag acccctggca gcaggcgcgc gtcgaagtag tctatcttgc 6300
atccttgcaa gtctagcgcc tgctgccatg cgcgggctgc aagcgcgcgc tcgtatgggt 6360
tgagtggggg accccatggc atggggtggg tgagcgcgga ggcgtacatg ccgcaaatgt 6420
cgtaaacgta gaggggctcc ctgagtattc caagatatgt agggtagcat cttccaccgc 6480
ggatgctggc gcgcacgtaa tcgtatagtt cgtgcgaggg agcgaggagg tcgggaccga 6540
ggttgctacg ggcgggctgc tctgctcgga agacgatctg cctgaagatg gcatgcgagt 6600
tggatgatat ggttggacgc tggaagacgt tgaagctagc gtctgtgaga cctaccgcgt 6660
cacgcacgaa ggaggcgtag gagtcgcgca gcttgttgac cagctcggcg gtgacctgca 6720
cgtctagggc gcagtagtcc agggtttcct tgatgatgtc atacttatcc tgtccctttt 6780
ttttccacag ctcgcggttg aggacaaact cttcgcggtc tttccagtac tcttggatcg 6840
gaaacccgtc ggcctccgaa cggtaagagc ctagcatgta gaactggttg acggcctggt 6900
aggcgcagca tcccttttct acgggtagcg cgtatgcctg tgcggccttc cggagcgagg 6960
tgtgggtgag cgcaaaggtg tccctgacca tgactttgag gtactggtat ttgaagtcaa 7020
tgtcgtcgca tccgccctgc tcccagagca aaaagtccgt gcgctttttg gaacgcgggt 7080
ttggcagggc gaaggtgaca tcgttgaaga gtatctttcc cgcgcgaggc ataaagttgc 7140
gtgtgatgcg gaagggtccc ggcacctcgg aacggttgtt aattacctgg gcggcgagca 7200
cgatctcgtc aaagccgttg atgttatggc ccacgatgta aagttccaag aagcgcgggg 7260
tgcccttgat ggagggcaat tttttaagtt cctcgtaggt gagctcttca ggggagctga 7320
gcccgtgctc tgacagggcc cagtctgcaa gatgagggtt ggaagcgacg aatgagctcc 7380
acaggtcacg ggccattagc gtctgcagct ggtcgcgaaa ggttctaaac tggcgaccta 7440
tggccatttt ttctggggtg atgcagtaga aggtaagcgt gtcttgttcc cagcggtccc 7500
atccaagttc cacggctagg tctctcgcgg cggttactag aggctcatct ccgccgaact 7560
tcatgaccag catgaagggc acgagctgct tcccaaaggc ccccatccaa gtataggtct 7620
ctacatcgta ggtgacaaag agacgctcgg tgcgaggatg cgagccgatc gggaagaact 7680
ggatctcccg ccaccagttg gaggagtggc tgttgatgtg gtgaaagtag aagtccctgc 7740
gacgggccga acactcgtgc tggcttttgt aaaaacgtgc gcagtactgg cagcggtgca 7800
cgggctgtac atcctgcacg aggttgacct gacgaccgcg cacaaggaag cagagtggga 7860
atttgagccc ctcgcctggc gggtttggct ggtggtcttc tacttcggct gcttgtcctt 7920
gaccgtctgg ctgctcgagg ggagttacgg tggatcgtac caccacgccg cgcgagctca 7980
aagtccagat gtccgcgcgc ggcggtcgga gcttgatgac aacatcgcgc agatgggagc 8040
tgtccatggt ctggagctcc cgcggcgtca ggtcaggcgg gagctcttgc aggtttacct 8100
cgcatagacg ggtgagggcg cgggctaggt ccaggtgata cctgatttcc aggggctggt 8160
tggtggcggc gtcgatggct tgcaagaggc cgcatccccg cggcgcgact acggtaccgc 8220
gcggcgggcg gtgggccgcg gggttgtcct gggatgcatc taaaagcggt gacgcgggcg 8280
ggcccccgga ggtagggggg gctccggacc cgccgggaga gggggcaggg gcacgtcggc 8340
gccgcgcgcg ggcaggagct ggtgctgcgc gcggaggttg ctggcgaacg cgacgacgcg 8400
gcggttgatc tcctgaatct ggcgcctctg cgtgaagacg acgggcccgg tgagcttgaa 8460
cctgaaagag agttcgacag aatcaatttc ggtgtcgttg acggcggcct ggcgcaaaat 8520
ctcctgcacg tctcctgagt tgtcttgata ggcgatctcg gccatgaact gctcgatctc 8580
ttcctcctgg agatctccgc gtccggctcg ctccacggtg gcggcgaggt cgttggagat 8640
gcgggccatg agctgcgaga aggcgttgag gcctccctcg ttccagacgc ggctgtagac 8700
cacgccccct tcggcatcgc gggcgcgcat gaccacctgc gcgagattga gctccacgtg 8760
ccgggcgaag acggcgtagt tgcgcaggcg ctgaaagagg tagttgaggg tggtggcggt 8820
gtgttctgcc acgaagaagt acataaccca gcgccgcaac gtggattcgt tgatatcccc 8880
caaggcctca aggcgctcca tggcctcgta gaagtccacg gcgaagttga aaaactggga 8940
gttgcgcgcc gacacggtca actcttcctc cagaagacgg atgagctcgg cgacagtgtc 9000
gcgcacctcg cgctcaaagg ctacaggggc ctcctcttct tcttcaatct cctcttccat 9060
aagggcctcc ccttcttctt cttccggtgg cggtggggga ggggcgcggc ggcgacgacg 9120
gcgcaccggg aggcggtcga caaagcgctc gatcatctcc ccgcggcgac ggcgcatggt 9180
ctcggtgacg gcgcggccgt tctcgcgggg gcgcagttgg aagacgccgc ccgtcatgtc 9240
ccggttatgg gttggcgggg tgctgccgtg cggcagggat acggcgctaa cgatgcatct 9300
caacaattgc tgtgtaggta ctccgccgcc gagggacctg agcgagtccg catcgaccgg 9360
atcggaaaac ctctcgagaa aggcgtctaa ccagtcacag tcgcaaggta ggctgagcac 9420
cgtggcgggc ggcagcgggc ggcggtcggg gttgtttctg gcggaggtgc tgctgatgat 9480
gtaattaaag taggcggtct tgagacggcg gatggtcgac agaagcacca tgtccttggg 9540
tccggcctgc tgaatgcgca ggcggtcggc catgccccag gcttcgtttt gacatcggcg 9600
caggtctttg tagtagtctt gcatgagcct ttctaccggc acttcttctt ctccttcctc 9660
ttgtcctgca tctcttgcat ctatcgctgc ggcggcggcg gagtttggcc gtaggtggcg 9720
ccctcttcct cccatgcgtg tgaccccgaa gcccctcagc ggttgaagca gggccaggtc 9780
ggcgacaacg cgctcggcta atatggcctg ctgcacctgc gtgagggtag actggaagtc 9840
atccatgtcc acaaagcggt ggtatgcgcc cgtgttgatg gtgtaagtgc agttggccat 9900
aacggaccag ttaacggtct ggtgacccgg ctgcgagagc tcggtgtacc tgagacgcga 9960
gtaagccctt gagtcaaaga cgtagtcgtt gcaagtccgc accaggtact ggtatcccac 10020
caaaaagtgc ggcggcggct ggcggtagag gggccagcgt agggtggccg gggctccggg 10080
ggcgaggtct tccaacataa ggcgatgata tccgtagatg tacctggaca tccaggtgat 10140
gccggcggcg gtggtggagg cgcgcgggaa gtcgcggacg cggttccaga tgttgcgcag 10200
cggcaaaaag tgctccatgg tcgggacgct ctggccggtc aggcgcgcgc agtcgttgac 10260
gctctagacc gtgcaaaagg agagcctgta agcgggcact cttccgtggt ctggtggata 10320
aattcgcaag ggtatcatgg cggacgaccg gggttcgaac cccggatccg gccgtccgcc 10380
gtgatccatg cggttaccgc ccgcgtgtcg aacccaggtg tgcgacgtca gacaacgggg 10440
gagtgctcct tttggcttcg ttccaggcgc ggcggctgct gcgctagctt ttttggccac 10500
tggccgcgcg cggcgtaagc ggttaggctg gaaagcgaaa gcattaagtg gctcgctccc 10560
tgtagccgga gggttatttt ccaagggttg agtcgcggga cccccggttc gagtctcggg 10620
ccggccggac tgcggcgaac gggggtttgc ctccccgtca tgcaagaccc cgcttgcaaa 10680
ttcctccgga aacagggacg agcccctttt ttgcttttcc cagatgcatc cggtgctgcg 10740
gcagatgcgc ccccctcctc agcagcggca agagcaagag cagcggcaga catgcagggc 10800
accctcccct cctcctaccg cgtcaggagg ggcgacatcc gcggctgacg cggcggcaga 10860
tggtgattac gaacccccgc ggcgccgggc ccgtcactac ctggacttgg aggaggggga 10920
gggcctggcg cggctaggag cgccctctcc tgagcggcac ccaagggtgc agctgaagcg 10980
tgacacgcgc gaggcgtacg tgccgcggca gaacctgttt cgcgaccgcg agggagagga 11040
gcccgaggag atgcgggatc gaaagtttca cgcggggcgc gagctgcggc atggcctgaa 11100
ccgcgagcgg ttgctgcgcg aggaggactt tgagcccgac gcgcggaccg ggattagtcc 11160
cgcgcgcgca cacgtggcgg ccgccgacct ggtaaccgcg tacgagcaga cggtgaacca 11220
ggagattaac tttcaaaaaa gctttaacaa ccacgtgcgc acgcttgtgg cgcgcgagga 11280
ggtggctata ggactgatgc atctgtggga ctttgtaagc gcgctggagc aaaacccaaa 11340
tagcaagccg ctcatggcgc agctgttcct tatagtacag cacagcaggg acaacgaggc 11400
attcagggat gcgctgctaa acatagtaga gcccgagggt cgctggctgc tcgatttgat 11460
aaacattctg cagagcatag tggtgcagga gcgcagcttg agcctggctg acaaggtggc 11520
cgccattaac tattccatgc tcagtctggg caagttttac gcccgcaaga tataccatac 11580
cccttacgtt cccatagaca aggaggtaaa gatcgagggg ttctacatgc gcatggcgct 11640
gaaggtgctt accttgagcg acgacctggg cgtttaccgc aacgagcgca tccacaaggc 11700
cgtgagcgtg agccggcggc gcgagctcag cgaccgcgag ctgatgcaca gcctgcaaag 11760
ggccctggct ggcacgggca gcggcgatag agaggccgag tcctactttg acgcgggcgc 11820
tgacctgcgc tgggccccaa gccgacgcgc cctggaggca gctggggccg gacctgggct 11880
ggcggtggca cccgcgcgcg ctggcaacgt cggcggcgtg gaggaatatg acgaggacga 11940
tgagtacgag ccagaggacg gcgagtacta agcggtgatg tttctgatca gatgatgcaa 12000
gacgcaacgg acccggcggt gcgggcggcg ctgcagagcc agccgtccgg ccttaactcc 12060
acggacgact ggcgccaggt catggaccgc atcatgtcgc tgactgcgcg caaccctgac 12120
gcgttccggc agcagccgca ggccaaccgg ctctccgcaa ttctggaagc ggtggtcccg 12180
gcgcgcgcaa accccacgca cgagaaggtg ctggcgatcg taaacgcgct ggccgaaaac 12240
agggccatcc ggcccgatga ggccggccta gtctacgacg cgctgcttca gcgcgtggct 12300
cgttacaaca gcggcaacgt gcagaccaac ctggaccggc tggtggggga tgtgcgcgag 12360
gccgtggcgc agcgtgagcg cgcgcaacag cagggcaacc tgggctccat ggttgcacta 12420
aacgccttcc tgagtacaca gcccgccaac gtgccgcggg gacaggagga ctacaccaac 12480
tttgtgagcg cactgcggct aatggtgact gagacaccgc aaagtgaggt gtaccagtcc 12540
gggccagact attttttcca gaccagtaga caaggcctgc agaccgtaaa cctgagccag 12600
gctttcaaga acttgcaggg gctgtggggg gtgcgggctc ccacaggcga ccgcgcgacc 12660
gtgtctagct tgctgacgcc caactcgcgc ctgttgctgc tgctaatagc gcccttcacg 12720
gacagtggca gcgtgtcccg ggacacatac ctaggtcact tgctgacact gtaccgcgag 12780
gccataggtc aggcgcatgt ggacgagcat actttccagg agattacaag tgtcagccgc 12840
gcgctggggc aggaggacac gggcagcctg gaggcaaccc tgaactacct gctgaccaac 12900
cggcggcaga agatcccctc gttgcacagt ttaaacagcg aggaggagcg catcttgcgc 12960
tatgtgcagc agagcgtgag ccttaacctg atgcgcgacg gggtaacgcc cagcgtggcg 13020
ctggacatga ccgcgcgcaa catggaaccg ggcatgtatg cctcaaaccg gccgtttatc 13080
aatcgcctaa tggactactt gcatcgcgcg gccgccgtga accccgagta tttcaccaat 13140
gccatcttga acccgcactg gctaccgccc cctggtttct acaccggggg atttgaggtg 13200
cccgagggta acgatggatt cctctgggac gacatagacg acagcgtgtt ttccccgcaa 13260
ccgcagaccc tgctagagtt gcaacagcgc gagcaggcag aggcggcgct gcgaaaggaa 13320
agctttcgca ggccaagcag cttgtccgat ctaggcgctg cggccccgcg gtcagatgct 13380
agtagcccat ttccaagctt gatagggtct cttaccagca ctcgcaccac ccgcccgcgc 13440
ctgctgggcg aggaggagta cctaaacaac tcgctgctgc agccgcagcg cgaaaagaac 13500
ctgcctccgg cgtttccgaa caacgggata gagagcctag tggacaagat gagtagatgg 13560
aagacgtatg cgcaggagca cagggatgtg cccggcccgc gcccgcccac ccgtcgtcaa 13620
aggcacgacc gtcagcgggg tctggtgtgg gaggacgatg actcggcaga cgacagcagc 13680
gtcctggatt tgggagggag tggcaacccg tttgcgcacc ttcgccccag gctggggaga 13740
atgttttaaa aaaaaaaaaa agcatgatgc aaaataaaaa actcaccaag gccatggcac 13800
cgagcgttgg ttttcttgta ttccccttag tatgcggcgc gcggcgatgt atgaggaagg 13860
tcctcctccc tcctacgaga gcgtggtgag cgcggcgcca gtggcggcgg cgctgggttc 13920
ccccttcgat gctcccctgg acccgccgtt cgtgcctccg cggtacctgc ggcctaccgg 13980
ggggagaaac agcatccgtt actctgagtt ggcaccccta ttcgacacca cccgtgtgta 14040
ccttgtggac aacaagtcaa cggatgtggc atccctgaac taccagaacg accacagcaa 14100
ctttctaacc acggtcattc aaaacaatga ctacagcccg ggggaggcaa gcacacagac 14160
catcaatctt gacgaccggt cgcactgggg cggcgacctg aaaaccatcc tgcataccaa 14220
catgccaaat gtgaacgagt tcatgtttac caataagttt aaggcgcggg tgatggtgtc 14280
gcgctcgctt actaaggaca aacaggtgga gctgaaatat gagtgggtgg agttcacgct 14340
gcccgagggc aactactccg agaccatgac catagacctt atgaacaacg cgatcgtgga 14400
gcactacttg aaagtgggca ggcagaacgg ggttctggaa agcgacatcg gggtaaagtt 14460
tgacacccgc aacttcagac tggggtttga cccagtcact ggtcttgtca tgcctggggt 14520
atatacaaac gaagccttcc atccagacat cattttgctg ccaggatgcg gggtggactt 14580
cacccacagc cgcctgagca acttgttggg catccgcaag cggcaaccct tccaggaggg 14640
ctttaggatc acctacgatg acctggaggg tggtaatatt cccgcactgt tggatgtgga 14700
cgcctaccag gcaagcttga aagatgacac cgaacagggc gggggtggcg caggcggcgg 14760
caacaacagt ggcagcggcg cggaagagaa ctccaacgcg gcagccgcgg caatgcagcc 14820
ggtggaggac atgaacgatc atgccattcg cggcgacacc tttgccacac gggcggagga 14880
gaagcgcgct gaggccgagg cagcggccga agctgccgcc cccgctgcgg aggctgcaca 14940
acccgaggtc gagaagcctc agaagaaacc ggtgattaaa cccctgacag aggacagcaa 15000
gaaacgcagt tacaacctaa taagtaatga cagcaccttc acccagtacc gcagctggta 15060
ccttgcatac aactacggcg accctcaggc cgggatccgc tcatggaccc tgctttgcac 15120
tcctgacgta acctgcggct cggagcaggt atactggtcg ttgcccgaca tgatgcaaga 15180
ccccgtgacc ttccgctcca cgagccagat cagcaacttt ccggtggtgg gcgccgagct 15240
gttgcccgtg cactccaaga gcttctacaa cgaccaggcc gtctactccc agctcatccg 15300
ccagtttacc tctctgaccc acgtgttcaa tcgctttccc gagaaccaga ttttggcgcg 15360
cccgccagcc cccaccatca ccaccgtcag tgaaaacgtt cctgctctca cagatcacgg 15420
gacgctaccg ctgcgcaaca gcatcggagg agtccagcga gtgaccatta ctgacgccag 15480
acgccgcacc tgcccctacg tttacaaggc cctgggcata gtctcgccgc gcgtcctatc 15540
gagccgcact ttttgagcaa gcatgtccat ccttatatcg cccagcaata acacaggctg 15600
gggcctgcgc ttcccaagca agatgtttgg cggggccaag aagcgctccg accaacaccc 15660
agtgcgcgtg cgcgggcact accgcgcgcc ctggggcgcg cacaaacgcg gccgcactgg 15720
gcgcaccacc gtcgatgacg ccatcgacgc ggtggtggag gaggcgcgca actacacgcc 15780
cacgccgccg ccagtgtcca ccgtggacgc ggccattcag accgtggtgc gcggagcccg 15840
gcgctacgct aaaatgaaga gacggcgaag gcgcgtagca cgtcgccacc gccgccgacc 15900
cggcactgcc gcccaacgcg cggcggcggc cctgcttaac cgcgcacgtc gcaccggccg 15960
acgggcggcc atgcgagccg ctcgaaggct ggccgcgggt attgtcactg tgccccccag 16020
gtccaggcga cgagcggccg ccgcagcagc cgcggccatt agtgctatga ctcagggtcg 16080
caggggcaac gtgtactggg tgcgcgactc ggttagcggc ctgcgcgtgc ccgtgcgcac 16140
ccgccccccg cgcaactaga ttgcaataaa aaactactta gactcgtact gttgtatgta 16200
tccagcggcg gcggcgcgca tcgaagctat gtccaagcgc aaaatcaaag aagagatgct 16260
ccaggtcatc gcgccggaga tctatggccc cccgaagaag gaagagcagg attacaagcc 16320
ccgaaagcta aagcgggtca aaaagaaaaa gaaagatgat gatgatgaac ttgacgacga 16380
ggtggaactg ttgcacgcga ccgcgcccag gcggcgggta cagtggaaag gtcgacgcgt 16440
aagacgtgtt ttgcgacccg gcaccaccgt agtctttacg cccggtgagc gctccacccg 16500
cacctacaag cgcgtgtatg atgaggtgta cggcgacgag gacttgcttg agcaggccaa 16560
cgagcgcctc ggggagtttg cctacggaaa gcggcataag gacatgctgg cgttgccgct 16620
ggacgagggc aacccaacac ctagcctaaa gcccgtgaca ctgcagcagg tgctgcccgc 16680
gcttgcaccg tccgaagaaa agcgcggcct aaagcgcgag tctggtgact tggcgcccac 16740
cgtgcagctc atggtgccca agcgccagcg actggaagat gtcttggaaa aaatgaccgt 16800
ggagcctggg ctggagcccg aggtccgcgt gcgaccaatc aagcaggtgg caccgggact 16860
gggcgtgcag accgtggacg ttcagatacc caccaccagt agcactagta ttgccactgc 16920
cacagagggc atggagacac aaacgtcccc ggtcgcctcg gcggtggcag atgccgcggt 16980
gcaggcggcc gctgcggccg cgtccaaaac ctctacggag gtgcaaacgg acccgtggat 17040
gtttcgcgtt tcagcccccc ggcgtccgcg ccgttcgagg aagtacggcg ccgccagcgc 17100
gctactgccc gaatatgccc tacatccttc catcgcgcct acccccggct atcgtggcta 17160
cacctaccgc cccagaagac gagcaactac ccgacgccga accaccactg gaacccgccg 17220
ccgccgtcgc cgtcgccagc ccgtgctggc cccgatttcc gtgcgcaggg tggctcgcga 17280
aggaggcagg accctggtgc tgccaacagc gcgctaccac cccagcatcg tttaaaagcc 17340
ggtctttgtg gttcttgcag atatggccct cacctgccgc ctccgtttcc cggtgccggg 17400
attccgagga agaatgcacc gtaggagggg catggccggc cacggcctga cgggcggcat 17460
gcgtcgtgcg caccaccggc ggcggcgcgc gtcgcaccgt cgcatgcgcg gcggtatcct 17520
gcccctcctt attccactga tcgccgcggc gattggcgcc gtgcccggaa ttgcatccgt 17580
ggccttgcag gcgcagagac actgattaaa aacaagttgc atgtggaaaa atcaaaataa 17640
aaagtctgga ctctcacgct cgcttggtcc tgtaactatt ttgtagaatg gaagacatca 17700
actttgcgtc tctggccccg cgacacggct cgcgcccgtt catgggaaac tggcaagata 17760
tcggcaccag caatatgagc ggtggcgcct tcagctgggg ctcgctgtgg agcggcatta 17820
aaaatttcgg ttccaccgtt aagaactatg gcagcaaggc ctggaacagc agcacaggcc 17880
aaatgctgag ggacaagttg aaagagcaaa atttccaaca aaaggtggta gatggcctgg 17940
cctctggcat tagcggggtg gtggacctgg ccaaccaggc agtgcaaaat aagattaaca 18000
gtaagcttga tcaccgccct cccgtagagg agccttcacc ggccgtggag acagtgttgc 18060
cagatgggcg tggcgaaaag cgcccgcgcc ccgacaggga agagactctg gtgacacaaa 18120
tcgacgagcc tccctcgtac gaggaggcgc taaagcaagg cctgcccacc acccgtccca 18180
tcgcgcccat ggctaccgga gtgttgggcc agcacacacc tgtaacgctg gacctgcctc 18240
cccccgctga cacccagcag aaacctgtgc tgccagggcc gtccgccgtt gttgtaaccc 18300
gccctagccg cgcgtccctg cgccgtgccg ccagcggtcc gcgatcgttg cggcccgtag 18360
ccagtggcaa ctggcaaagc acactgaaca gcatcgtggg tctgggggtg caatccctaa 18420
agcgccgacg atgcttttga atagctaacg tgtcgtatgt gtgtcatgta tgcgtccatg 18480
tcgccgccag aggagctgct gagtcgccgc gcgcccgctt tccaagatgg ctaccccttc 18540
gatgatgccg cagtggtctt acatgcacat ctcgggccag gacgcctcgg agtacctgag 18600
ccccgggctg gtgcagttcg cccgcgccac cgagacgtac ttcagcctga ataacaagtt 18660
tagaaacccc acggtggcgc ctacgcacga cgtgaccaca gaccggtctc agcgtttgac 18720
gctgcggttt atccccgtgg accgcgagga taccgcatac tcgtacaagg cgcggtttac 18780
cctggctgtg ggtgacaacc gtgtgcttga catggcttcc acatactttg acattcgcgg 18840
cgtgctggac cggggcccca cttttaaacc ctactccggc actgcctaca acgctctagc 18900
ccccaagggc gctcccaatt cctgcgagtg ggaacaagaa gaaccaactc aggaaatggc 18960
tgaagaactt gaagatgagg aggaggcaga ggaggaggag gcagaggagg aggcagaagc 19020
accacaagct gatcagaagg ttaagaagac tcatgtatat gctcaggctc ctttggcagg 19080
ggaaaaaatt accgccaatg gcttacaaat agtttctgat acccaaactg aaggcaatcc 19140
agtttttgcc gatcccactt atcaacctga acctcaggtt ggagaatctc agtggaatga 19200
agctgaagca actgcatctg gaggcagagt actaaaaaag actactccca tgaaaccatg 19260
ctacggatcg tatgccagac ctacaaataa aaatgggggt caaggtatac tagtagcaaa 19320
caaccaaggt gctctagagt ctaaagttga aatgcagttt tttgccccct ctggcactgc 19380
catgaatgaa agaaatgctg ttcagccaag tattgttttg tacagtgagg atgttaatat 19440
ggaaactcct gatactcaca tttcatacaa accaagcaaa actgatgaaa actctaaggc 19500
tatgttgggt caacaagcaa tgccaaacag acccaattac atcgctttta gggacaattt 19560
tattggcctt atgtattaca acagcactgg taacatgggt gtccttgctg gacaagcatc 19620
acagctaaat gccgtggtag acttgcagga cagaaacaca gagctgtcat atcaactttt 19680
gcttgattct attggcgata gaaccagata cttttccatg tggaatcagg ctgtagacag 19740
ctatgatcca gatgtcagaa tcattgaaaa tcatggaact gaggatgagt tgccaaatta 19800
ctgcttccca cttggcggta taggggtaac tgacacctac caaggtataa aatcaaacgg 19860
aaacggtaat cctcaaaact ggaccaaaaa tgacgatttt gcggcacgta atgaaatagg 19920
tgtgggaaac aactttgccc tggagattaa ccttaatgcc aacctatgga gaaatttcct 19980
ctactccaac attgcactgt acctgcctga caagctaaaa tacactccta caaatgtgga 20040
aatatctccc aaccctaatt catacgatta tatgaacaaa cgagtggtgg ctcccgggtt 20100
ggtggattgc tacattaacc ttggagcgcg ttggtcattg gactacatgg acaacgtcaa 20160
cccctttaac catcaccgca atgcgggcct acgctaccgc tccatgttgc tgggcaacgg 20220
tcgctacgtg ccctttcaca tccaggttcc tcagaagttt tttgccatta agaacctcct 20280
actcttgccg ggctcataca cctacgagtg gaacttcagg aaagatgtta acatggtcct 20340
acaaagctcc ctaggaaacg acctaagagt tgacggagcc agcattaagt ttgacagcat 20400
ttgcctctac gccacctttt ttccgatggc ccacaacacc gcctcaacgc ttgaagccat 20460
gcttagaaac gacaccaacg accaatcctt taacgactac ctatccgccg ccaacatgct 20520
ttaccccata cccgccaacg ccaccaacgt gcccatctct atcccctcgc gcaactgggc 20580
ggctttccga ggctgggcct ttacgcgcct taagactaag gaaaccccat ccctgggttc 20640
cggctacgac ccttactata cctactctgg ctccataccc tacctagacg gaacctttta 20700
ccttaatcac accttcaaaa aggtggccat cacctttgac tcttctgtta gctggcctgg 20760
caatgaccgt ctgcttaccc ccaacgagtt tgagatcaag cgttcagttg acggagaggg 20820
ctacaacgtt gcccaatgca acatgaccaa agactggttc ttggtacaga tgctagccaa 20880
ctacaacata ggctaccagg gcttttatat cccagaaagc tataaggacc gcatgtactc 20940
cttctttaga aacttccagc ccatgagccg tcaggtggtg gacgatacca aatacaagga 21000
ctaccaacag gtgggcatcc tccaccagca caataactct ggctttgttg gttacctcgc 21060
tcccaccatg cgagagggac aggcctaccc cgccaacttc ccctacccgc ttataggcaa 21120
gaccgcggtt gacagtatta cccagaaaaa gtttctttgc gaccgcaccc tttggcgcat 21180
tccattctcc agtaacttta tgtccatggg tgcactcaca gacctgggcc aaaaccttct 21240
ctatgcaaac tccgcccacg cgctagatat gacttttgag gtggatccca tggacgagcc 21300
cacccttctt tatgttttgt ttgaagtctt tgacgtggtc cgtgtgcacc agccgcaccg 21360
cggcgtcatc gagaccgtgt acctgcgcac gcccttctcg gctggcaacg ccacaacata 21420
aagaagcaag caacatcaac aacagctgcc gccatgggct ccagtgagca ggaactaaaa 21480
gccattgtca aagatcttgg ttgtgggcca tattttttgg gcacctatga caagcgcttc 21540
ccaggctttg tttccccaca caagctcgcc tgcgccatag ttaacacggc cggtcgcgag 21600
actgggggcg tacactggat ggcctttgcc tggaacccgc gctcaaaaac atgctacctc 21660
tttgagccct ttggcttttc tgaccaacgt ctcaagcagg tttaccagtt tgagtacgag 21720
tcactcctgc gccgtagcgc cattgcctct tcccccgacc gctgtataac gctggaaaag 21780
tccacccaaa gcgtgcaggg gcccaactcg gccgcctgtg gcctattctg ctgcatgttt 21840
ctccacgcct ttgccaactg gccccaaact cccatggatc acaaccccac catgaacctt 21900
attaccgggg tacccaactc catgcttaac agtccccagg tacagcccac cctgcgtcgc 21960
aaccaggaac agctctacag cttcctggag cgccactcgc cctacttccg cagccacagt 22020
gcgcagatta ggagcgccac ttctttttgt cacttgaaaa acatgtaaaa ataatgtact 22080
aggagacact ttcaataaag gcaaatgttt ttatttgtac actctcgggt gattatttac 22140
ccccaccctt gccgtctgcg ccgtttaaaa atcaaagggg ttctgccgcg catcgctatg 22200
cgccactggc agggacacgt tgcgatactg gtgtttagtg ctccacttaa actcaggcac 22260
aaccatccgc ggcagctcgg tgaagttttc actccacagg ctgcgcacca tcaccaacgc 22320
gtttagcagg tcgggtgccg atatcttgaa gtcgcagttg gggcctccgc cctgcgcgcg 22380
cgagttgcga tacacagggt tgcagcactg gaacactatt agcgccgggt ggtgcacgct 22440
ggccagcacg ctcttgtcgg agatcagatc cgcgtccagg tcctccgcgt tgctcagggc 22500
gaacggagtc aactttggta gctgccttcc caaaaagggt gcatgcccag gctttgagtt 22560
gcactcgcac cgtagtggca tcagaaggtg accgtgcccg gtctgggcgt taggatacag 22620
cgcctgcatg aaagccttga tctgcttaaa agccacctga gcctttgcgc cttcagagaa 22680
gaacatgccg caagacttgc cggaaaactg attggccgga caggccgcgt catgcacgca 22740
gcaccttgcg tcggtgttgg agatctgcac cacatttcgg ccccaccggt tcttcacgat 22800
cttggccttg ctagactgct ccttcagcgc gcgctgcccg ttttcgctcg tcacatccat 22860
ttcaatcacg tgctccttat ttatcataat gctcccgtgt agacacttaa gctcgccttc 22920
gatctcagcg cagcggtgca gccacaacgc gcagcccgtg ggctcgtggt gcttgtaggt 22980
tacctctgca aacgactgca ggtacgcctg caggaatcgc cccatcatcg tcacaaaggt 23040
cttgttgctg gtgaaggtca gctgcaaccc gcggtgctcc tcgtttagcc aggtcttgca 23100
tacggccgcc agagcttcca cttggtcagg cagtagcttg aagtttgcct ttagatcgtt 23160
atccacgtgg tacttgtcca tcaacgcgcg cgcagcctcc atgcccttct cccacgcaga 23220
cacgatcggc aggctcagcg ggtttatcac cgtgctttca ctttccgctt cactggactc 23280
ttccttttcc tcttgcgtcc gcataccccg cgccactggg tcgtcttcat tcagccgccg 23340
caccgtgcgc ttacctccct tgccgtgctt gattagcacc ggtgggttgc tgaaacccac 23400
catttgtagc gccacatctt ctctttcttc ctcgctgtcc acgatcacct ctggggatgg 23460
cgggcgctcg ggcttgggag aggggcgctt ctttttcttt ttggacgcaa tggccaaatc 23520
cgccgtcgag gtcgatggcc gcgggctggg tgtgcgcggc accagcgcat cttgtgacga 23580
gtcttcttcg tcctcggact cgagacgccg cctcagccgc ttttttgggg gcgcgcgggg 23640
aggcggcggc gacggcgacg gggacgacac gtcctccatg gttggtggac gtcgcgccgc 23700
accgcgtccg cgctcggggg tggtttcgcg ctgctcctct tcccgactgg ccatttcctt 23760
ctcctatagg cagaaaaaga tcatggagtc agtcgagaag gaggacagcc taaccgcccc 23820
ctttgagttc gccaccaccg cctccaccga tgccgccaac gcgcctacca ccttccccgt 23880
cgaggcaccc ccgcttgagg aggaggaagt gattatcgag caggacccag gttttgtaag 23940
cgaagacgac gaggatcgct cagtaccaac agaggataaa aagcaagacc aggacgacgc 24000
agaggcaaac gaggaacaag tcgggcgggg ggaccaaagg catggcgact acctagatgt 24060
gggagacgac gtgctgttga agcatctgca gcgccagtgc gccattatct gcgacgcgtt 24120
gcaagagcgc agcgatgtgc ccctcgccat agcggatgtc agccttgcct acgaacgcca 24180
cctgttctca ccgcgcgtac cccccaaacg ccaagaaaac ggcacatgcg agcccaaccc 24240
gcgcctcaac ttctaccccg tatttgccgt gccagaggtg cttgccacct atcacatctt 24300
tttccaaaac tgcaagatac ccctatcctg ccgtgccaac cgcagccgag cggacaagca 24360
gctggccttg cggcagggcg ctgtcatacc tgatatcgcc tcgctcgacg aagtgccaaa 24420
aatctttgag ggtcttggac gcgacgagaa acgcgcggca aacgctctgc aacaagaaaa 24480
cagcgaaaat gaaagtcact gtggagtgct ggtggaactt gagggtgaca acgcgcgcct 24540
agccgtgctg aaacgcagca tcgaggtcac ccactttgcc tacccggcac ttaacctacc 24600
ccccaaggtt atgagcacag tcatgagcga gctgatcgtg cgccgtgcac gacccctgga 24660
gagggatgca aacttgcaag aacaaaccga ggagggccta cccgcagttg gcgatgagca 24720
gctggcgcgc tggcttgaga cgcgcgagcc tgccgacttg gaggagcgac gcaagctaat 24780
gatggccgca gtgcttgtta ccgtggagct tgagtgcatg cagcggttct ttgctgaccc 24840
ggagatgcag cgcaagctag aggaaacgtt gcactacacc tttcgccagg gctacgtgcg 24900
ccaggcctgc aaaatttcca acgtggagct ctgcaacctg gtctcctacc ttggaatttt 24960
gcacgaaaac cgcctcgggc aaaacgtgct tcattccacg ctcaagggcg aggcgcgccg 25020
cgactacgtc cgcgactgcg tttacttatt tctgtgctac acctggcaaa cggccatggg 25080
cgtgtggcag cagtgcctgg aggagcgcaa cctgaaggag ctgcagaagc tgctaaagca 25140
aaacttgaag gacctatgga cggccttcaa cgagcgctcc gtggccgcgc acctggcgga 25200
cattatcttc cccgaacgcc tgcttaaaac cctgcaacag ggtctgccag acttcaccag 25260
tcaaagcatg ttgcaaaact ttaggaactt tatcctagag cgttcaggaa ttctgcccgc 25320
cacctgctgt gcgcttccta gcgactttgt gcccattaag taccgtgaat gccctccgcc 25380
gctttggggt cactgctacc ttctgcagct agccaactac cttgcctacc actccgacat 25440
catggaagac gtgagcggtg acggcctact ggagtgtcac tgtcgctgca acctatgcac 25500
cccgcaccgc tccctggtct gcaattcgca actgcttagc gaaagtcaaa ttatcggtac 25560
ctttgagctg cagggtccct cgcctgacga aaagtccgcg gctccggggt tgaaactcac 25620
tccggggctg tggacgtcgg cttaccttcg caaatttgta cctgaggact accacgccca 25680
cgagattagg ttttacgaag accaatcccg cccgccaaat gcggagctta ccgcctgcgt 25740
cattacccag ggccacatcc ttggccaatt gcaagccatc aacaaagccc gccaagagtt 25800
tctgctacga aagggacggg gggtttacct ggacccccag tccggcgagg agctcaaccc 25860
aatccccccg ccgccgcagc cctatcagca gccgcgggcc cttgcttccc aggatggcac 25920
ccaaaaagaa gctgcagctg ccgccgccgc cacccacgga cgaggaggaa tactgggaca 25980
gtcaggcaga ggaggttttg gacgaggagg aggagatgat ggaagactgg gacagcctag 26040
acgaagcttc cgaggccgaa gaggtgtcag acgaaacacc gtcaccctcg gtcgcattcc 26100
cctcgccggc gccccagaaa ttggcaaccg ttcccagcat cgctacaacc tccgctcctc 26160
aggcgccgcc ggcactgccc gttcgccgac ccaaccgtag atgggacacc actggaacca 26220
gggccggtaa gtctaagcag ccgccgccgt taacccaaga gcaacaacag cgccaaggct 26280
accgctcgtg gcgcgggcac aagaacgcca tagttgcttg cttgcaagac tgtgggggca 26340
acatctcctt cgcccgccgc tttcttctct accatcacgg cgtggccttc ccccgtaaca 26400
tcctgcatta ctaccgtcat ctctacagcc cctactgcac cggcggcagc ggcagcggca 26460
gcaacagcag cggtcacaca gaagcaaagg cgaccggata gcaagactct gacaaagccc 26520
aagaaatcca cagcggcggc agcagcagga ggaggagcgc tgcgtctggc gtccaacgaa 26580
cccgtatcga cccgcgagct tagaaacagg atttttccca ctctgtatgc tatatttcaa 26640
caaagcaggg gccaagaaca agagctaaaa ataaaaaaca ggtctctgcg ctccctcacc 26700
cgcagctgcc tgtatcacaa aagcgaagat cagcttcggc gcacgctgga agacgcggag 26760
gctctcttca gcaaatactg cgcgctgact cttaaggact agtttcgcgc cctttctcaa 26820
atttaagcgc gaaaactacg tcatctccag cggccacacc cggcgccagc acctgtcgtc 26880
agcgccatta tgagcaagga aattcccacg ccctacatgt ggagttacca gccacaaatg 26940
ggacttgcgg ctggagctgc ccaagactac tcaacccgaa taaactacat gagcgcggga 27000
ccccacatga tatcccgggt caacggaatc cgcgcccacc gaaaccgaat tctcctcgaa 27060
caggcggcta ttaccaccac acctcgtaat aaccttaatc cccgtagttg gcccgctgcc 27120
ctggtgtacc aggaaagtcc cgctcccacc actgtggtac ttcccagaga cgcccaggcc 27180
gaagttcaga tgactaactc aggggcgcag cttgcgggcg gctttcgtca cagggtgcgg 27240
tcgccaggac agggtataac tcacctgaaa atcagagggc gaggtattca gctcaacgac 27300
gagtcggtga gctcctctct tggtctccgt ccggacggga catttcagat cggcggcgct 27360
ggccgctctt catttacgcc ccgtcaggcg atcctaactc tgcagacctc gtcctcggag 27420
ccgcgctccg gaggcattgg aactctacaa tttattgagg agttcgtgcc ttcagtttac 27480
ttcaacccct tttctggacc tcccggccac tacccggacc agtttattcc caactttgac 27540
gcggtgaaag actcggcgga cggctacgac tgaatgacca gtggagaggc agagcaactg 27600
cgcctgacac acctcgacca ctgccgccgc cacaagtgct ttgcccgcgg ctccggtgag 27660
ttttgttact ttgaattgcc cgaagagcat atcgagggcc cggcgcacgg cgtccggctc 27720
accacccagg tagagcttac acgtagcctg attcgggagt ttaccaagcg ccccctgcta 27780
gtggagcggg agcggggtcc ctgtgttctg accgtggttt gcaactgtcc taaccctgga 27840
ttacatcaag atctttgttg tcatctctgt gctgagtata ataaatacag aaattagaat 27900
ctactggggc tcctgtcgcc atcctgtgaa cgccaccgtt tttacccacc caaagcagac 27960
caaagcaaac ctcacctccg gtttgcacaa gcgggccaat aagtacctta cctggtactt 28020
taacggctct tcatttgtaa tttacaacag tttccagcga gacgaagtaa gtttgccaca 28080
caaccttctc ggcttcaact acaccgtcaa gaaaaacacc accaccaccc tcctcacctg 28140
ccgggaacgt acgagtgcgt caccggttgc tgcgcccaca cctacagcct gagcgtaacc 28200
agacattact cccatttttc caaaacagga ggtgagctca actcccggaa ctcaggtcaa 28260
aaaagcattt tgcggggtgc tgggattttt taattaagta tatgagcaat tcaagtaact 28320
ctacaagctt gtctaatttt tctggaattg gggtcggggt tatccttact cttgtaattc 28380
tgtttattct tatactagca cttctgtgcc ttagggttgc cgcctgctgc acgcacgttt 28440
gtacctattg tcagcttttt aaacgctggg ggcgacatcc aagatgagat taaatgagac 28500
atgattcctc gagttcttat attattgacc cttgttgcgc ttttctgtgc gtgctctaca 28560
ttggccgcgg tcgctcacat cgaagtagat tgcatcccac ctttcacagt ttacctgctt 28620
tacggatttg tcacccttat cctcatctgc agcctcgtca ctgtagtcat cgccttcatt 28680
cagttcattg actgggtttg tgtgcgcatt gcgtacctca ggcaccatcc gcaatacaga 28740
gacaggacta tagctgatct tctcagaatt ctttaattat gaaacggagt gtcatttttg 28800
ttttgctgat tttttgcgcc ctacctgtgc tttgctccca aacctcagcg cctcccaaaa 28860
gacatatttc ctgcagattc actcaaatat ggaacattcc cagctgctac aacaaacaga 28920
gcgatttgtc agaagcctgg ttatacgcca tcatctctgt catggttttt tgcagtacca 28980
tttttgccct agccatatat ccataccttg acattggctg gaatgccata gatgccatga 29040
accaccctac tttcccagtg cccgctgtca taccactgca acaggttatt gccccaatca 29100
atcagcctcg ccccccttct cccaccccca ctgagattag ctactttaat ttgacaggtg 29160
gagatgactg aatctctaga tctagaattg gatggaatta acaccgaaca gcgcctacta 29220
gaaaggcgca aggcggcgtc cgagcgagaa cgcctaaaac aagaagttga agacatggtt 29280
aacctacacc agtgtaaaag aggtatcttt tgtgtggtca agcaggccaa acttacctac 29340
gaaaaaacca ctaccggcaa ccgcctcagc tacaagctac ccacccagcg ccaaaaactg 29400
gtgcttatgg tgggagaaaa acctatcacc gtcacccagc actcggcaga aacagagggc 29460
tgcctgcact tcccctatca gggtccagag gacctctgca ctcttattaa aaccatgtgt 29520
ggtattagag atcttattcc attcaactaa cataaacaca caataaatta cttacttaaa 29580
atcagtcagc aaatctttgt ccagcttatt cagcatcacc tcctttcctt cctcccaact 29640
ctggtatctc agccgccttt tagctgcaaa ctttctccaa agtttaaatg ggatgtcaaa 29700
ttcctcatgt tcttgtccct ccgcacccac tatcttcata ttgttgcaga tgaaacgcgc 29760
cagaccgtct gaagacacct tcaaccccgt gtatccatat gacacagaaa ccgggcctcc 29820
aactgtgccc tttcttaccc ctccatttgt ttcacccaat ggtttccaag aaagtccccc 29880
tggagttctc tctctacgcg tctccgaacc tttggacacc tcccacggca tgcttgcgct 29940
taaaatgggc agcggtctta ccctagacaa ggccggaaac ctcacctccc aaaatgtaac 30000
cactgttact cagccactta aaaaaacaaa gtcaaacata agtttggaca cctccgcacc 30060
acttacaatt acctcaggcg ccctaacagt ggcaaccacc gctcctctga tagttactag 30120
cggcgctctt agcgtacagt cacaagcccc actgaccgtg caagactcca aactaagcat 30180
tgctactaaa gggcccatta cagtgtcaga tggaaagcta gccctgcaaa catcagcccc 30240
cctctctggc agtgacagcg acacccttac tgtaactgca acacccccgc taactactgc 30300
cacgggtagc ttgggcatta acatggaaga tcctatttat gtaaataatg gaaaaatagg 30360
aattaaaata agcggtcctt tgcaagtagc acaaaactcc gatacactaa cagtagttac 30420
tggaccaggt gtcaccgttg aacaaaactc ccttagaacc aaagttgcag gagctattgg 30480
ttatgattca tcaaacaaca tggaaattaa aacgggcggt ggcatgcgta taaataacaa 30540
cttgttaatt ctagatgtgg attacccatt tgatgctcaa acaaaactac gtcttaaact 30600
ggggcaggga cccctgtata ttaatgcatc tcataacttg gacataaact ataacagagg 30660
cctatacctt tttaatgcat caaacaatac taaaaaactg gaagttagca taaaaaaatc 30720
cagtggacta aactttgata atactgccat agctataaat gcaggaaagg gtctggagtt 30780
tgatacaaac acatctgagt ctccagatat caacccaata aaaactaaaa ttggctctgg 30840
cattgattac aatgaaaacg gtgccatgat tactaaactt ggagcgggtt taagctttga 30900
caactcaggg gccattacaa taggaaacaa aaatgatgac aaacttaccc tgtggacaac 30960
cccagaccca tctcctaact gcagaattca ttcagataat gactgcaaat ttactttggt 31020
tcttacaaaa tgtgggagtc aagtactagc tactgtagct gctttggctg tatctggaga 31080
tctttcatcc atgacaggca ccgttgcaag tgttagtata ttccttagat ttgaccaaaa 31140
cggtgttcta atggagaact cctcacttaa aaaacattac tggaacttta gaaatgggaa 31200
ctcaactaat gcaaatccat acacaaatgc agttggattt atgcctaacc ttctagccta 31260
tccaaaaacc caaagtcaaa ctgctaaaaa taacattgtc agtcaagttt acttgcatgg 31320
tgataaaact aaacctatga tacttaccat tacacttaat ggcactagtg aatccacaga 31380
aactagcgag gtaagcactt actctatgtc ttttacatgg tcctgggaaa gtggaaaata 31440
caccactgaa acttttgcta ccaactctta caccttctcc tacattgccc aggaataaag 31500
aatcgtaaac ctgttgcatg ttatgtttca acgtgtttat ttttcaattg cagaaaattt 31560
caagtcattt ttcattcagt agtatagccc caccaccaca tagcttatac agatcaccgt 31620
accttatcaa actcacagaa ccctagtatt caacctgcca cctccctccc aacacacaga 31680
gtacacagtc ctttctcccc ggctggcctt aaaaagcatc atatcatggg taacagacat 31740
attcttaggt gttatattcc acacggtttc ctgtcgagcc aaacgctcat cagtgatatt 31800
aataaactcc ccgggcagct cacttaagtt catgtcgctg tccagctgct gagccacagg 31860
ctgctgtcca acttgcggtt gcttaacggg cggcgaagga gaagtccacg cctacatggg 31920
ggtagagtca taatcgtgca tcaggatagg gcggtggtgc tgcagcagcg cgcgaataaa 31980
ctgctgccgc cgccgctccg tcctgcagga atacaacatg gcagtggtct cctcagcgat 32040
gattcgcacc gcccgcagca taaggcgcct tgtcctccgg gcgcagcagc gcaccctgat 32100
ctcacttaaa tcagcacagt aactgcagca cagcaccaca atattgttca aaatcccaca 32160
gtgcaaggcg ctgtatccaa agctcatggc ggggaccaca gaacccacgt ggccatcata 32220
ccacaagcgc aggtagatta agtggcgacc cctcataaac acgctggaca taaacattac 32280
ctcttttggc atgttgtaat tcaccacctc ccggtaccat ataaacctct gattaaacat 32340
ggcgccatcc accaccatcc taaaccagct ggccaaaacc tgcccgccgg ctatacactg 32400
cagggaaccg ggactggaac aatgacagtg gagagcccag gactcgtaac catggatcat 32460
catgctcgtc atgatatcaa tgttggcaca acacaggcac acgtacatac acttcctcag 32520
gattacaagc tcctcccgcg tcagaaccat atcccaggga acaacccatt cctgaatcag 32580
cgtaaatccc acactgcagg gaagacctcg cacgtaactc acgttgtgca ttgtcaaagt 32640
gttacattcg ggcagcagcg gatgatcctc cagtatggta gcgcgggttt ctgtctcaaa 32700
aggaggtaga cgatccctac tgtacggagt gcgccgagac aaccgagatc gtgttggtcg 32760
tagtgtc 32767
Claims (5)
1.一种复制型人腺病毒在制备治疗肿瘤的制剂中的应用,其特征在于,所述复制型人腺病毒核苷酸序列如SEQ ID NO:21所示;
所述复制型人腺病毒的构建方法包括:
S1)PCR扩增获得NBOV1901基因组的左右两端,连接在抗性载体质粒A得到pT-NBOV1901(L+R),线性化后与NBOV1901基因组重组得到基因组质粒pNBOV1901;所述NBOV1901基因组的全序列的GenBank号为:MH558113 .1;
S2)PCR扩增获得从SrfI至整个E3区左右臂连接至抗性载体质粒B上,线性化后与PacI酶切的NBOV1901进行重组,得到去除SrfI至整个E3区的基因组质粒pNBOV1901△E3-SrfI;
S3)以NBOV1901基因组为模板,PCR扩增获得E3gp19K上游片段:SrfI至E3gp19K,和E3gp19K下游片段:E3gp19K至E3区包含E3-14.7K基因片段,将E3gp19K上游片段、E3gp19K下游片段和酶切后的构建载体三个片段重组连接至pNBOV1901△E3-SrfI左右臂之间,线性化后与pNBOV1901△E3-SrfI进行重组,得到修改了SrfI酶切位点的基因组质粒pNBOV1901△E3gp19K;
S4)PCR扩增获得E1区左右臂连接至抗性载体质粒B上,线性化后与SrfI酶切的pNBOV1901△E3gp19K重组,得到去除E1区的基因组质粒pNBOV1901△E3gp19K△E1;
S5)PCR扩增获得去除E1b19K、pRB基因的E1区基因组,连接至含有E1区左右臂的抗性载体质粒B上,线性化后与酶切后的pNBOV1901△E3gp19K△E1进行重组,得到敲除E1b19K、pRB基因的基因组质粒pNBOV1910,即所述复制型人腺病毒;
所述PCR扩增获得去除E1b19K、pRB基因的E1区基因组的引物序列如SEQ ID NO:16-SEQ ID NO:20所示;
所述抗性载体质粒A和所述抗性载体质粒B具有不同的抗性;
所述肿瘤为非小细胞肺癌。
2.一种用于治疗非小细胞肺癌的组合物,其特征在于:其含有权利要求1中所述的复制型人腺病毒。
3.根据权利要求2所述的组合物,其特征在于,所述组合物中包括:a)免疫调控剂;b)免疫调控细胞;c)放射性治疗物;d)光疗法化合物;或e)化学治疗化合物中的至少一种。
4.根据权利要求2所述的组合物,其特征在于,所述组合物中还含有药学上可接受的佐剂、稀释剂或赋形剂。
5.组合物在制备治疗肿瘤制剂中的应用,其特征在于:所述组合物如权利要求2~4任一项所述;所述肿瘤为非小细胞肺癌。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010523284.8A CN113774031B (zh) | 2020-06-10 | 2020-06-10 | 一种复制型人腺病毒及其应用 |
PCT/CN2021/088761 WO2021249035A1 (zh) | 2020-06-10 | 2021-04-21 | 一种复制型人腺病毒及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010523284.8A CN113774031B (zh) | 2020-06-10 | 2020-06-10 | 一种复制型人腺病毒及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113774031A CN113774031A (zh) | 2021-12-10 |
CN113774031B true CN113774031B (zh) | 2024-04-02 |
Family
ID=78834565
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010523284.8A Active CN113774031B (zh) | 2020-06-10 | 2020-06-10 | 一种复制型人腺病毒及其应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN113774031B (zh) |
WO (1) | WO2021249035A1 (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101128593A (zh) * | 2004-12-31 | 2008-02-20 | 佩尔·松内·霍尔姆 | 逆转动物细胞中多种抗性的方法 |
CN101643750A (zh) * | 2009-09-11 | 2010-02-10 | 郑州大学 | 靶向性溶肿瘤腺病毒载体Ad-TD-gene的构建方法及应用 |
CN109576231A (zh) * | 2017-09-28 | 2019-04-05 | 杭州康万达医药科技有限公司 | 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103110939A (zh) * | 2012-10-23 | 2013-05-22 | 郑州大学 | 诱导肿瘤特异性免疫的疫苗及其应用 |
CN106520778A (zh) * | 2015-09-09 | 2017-03-22 | 北京锤特生物科技有限公司 | 改造的白介素12及其在制备治疗肿瘤的药物中的用途 |
US10232053B2 (en) * | 2016-12-30 | 2019-03-19 | Trieza Therapeutics, Inc. | Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer |
-
2020
- 2020-06-10 CN CN202010523284.8A patent/CN113774031B/zh active Active
-
2021
- 2021-04-21 WO PCT/CN2021/088761 patent/WO2021249035A1/zh active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101128593A (zh) * | 2004-12-31 | 2008-02-20 | 佩尔·松内·霍尔姆 | 逆转动物细胞中多种抗性的方法 |
CN101643750A (zh) * | 2009-09-11 | 2010-02-10 | 郑州大学 | 靶向性溶肿瘤腺病毒载体Ad-TD-gene的构建方法及应用 |
CN109576231A (zh) * | 2017-09-28 | 2019-04-05 | 杭州康万达医药科技有限公司 | 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 |
Non-Patent Citations (2)
Title |
---|
GenBank:MH558113.1.Human mastadenovirus C strain human/CHN/GD2467/2017/87'[P1H1F2], complete genome.《NCBI》.2019,全文. * |
许琨.新型溶肿瘤腺病毒Ad-TD-RFP对人鼻咽癌的治疗作用.《中国优秀硕士学位论文全文数据库医药卫生科技辑(月刊)》.2012,(第10期),摘要、正文第17-19页"4本实验在肿瘤研究中的意义"部分. * |
Also Published As
Publication number | Publication date |
---|---|
CN113774031A (zh) | 2021-12-10 |
WO2021249035A1 (zh) | 2021-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003271737B2 (en) | Means and methods for the production of adenovirus vectors | |
RU2361611C2 (ru) | Конструирование рекомбинанта онколитического аденовируса, специфически экспрессирующего иммуномодуляторный фактор gm-csf в опухолевых клетках, и его применение | |
JP6375273B2 (ja) | 腫瘍選択的e1aおよびe1b変異体 | |
CN111658670A (zh) | 溶瘤腺病毒载体与过继t细胞治疗组合物及其用途 | |
Rivera et al. | Mode of transgene expression after fusion to early or late viral genes of a conditionally replicating adenovirus via an optimized internal ribosome entry site in vitro and in vivo | |
KR20140139509A (ko) | 터미널 말단이 변경된 재조합 아데노바이러스의 배치 | |
AU780613B2 (en) | Replication-competent anti-cancer vectors | |
CZ301506B6 (cs) | Selektivne se replikující rekombinantní virový vektor a zpusob jeho prípravy, farmaceutická formulace, zpusob usmrcení bunky s defektní dráhou, transformovaná bunka a promotor reagující na dráhu p53 a TGF-ß | |
US20020019051A1 (en) | Chimeric adenoviral vectors | |
WO1999055831A2 (en) | Adenoviral vectors for treating disease | |
US20050002965A1 (en) | Recombinant adenovirus with enhanced therapeutic effect and pharmaceutical composition comprising said recombinant adenovirus | |
AU781775B2 (en) | Adenoviral vectors for treating disease | |
CN113774031B (zh) | 一种复制型人腺病毒及其应用 | |
Yu et al. | A simplified system for generating recombinant E3-deleted canine adenovirus-2 | |
JP2004519201A (ja) | キメラアデノウイルスベクター | |
US7829329B2 (en) | Adenoviral vectors for treating disease | |
Chaurasiya et al. | Adenoviral vector construction I: mammalian systems | |
US20060275262A1 (en) | Conditionally replicating viruses and methods for cancer virotherapy | |
JP2002527455A (ja) | 組換え欠失アデノウイルスベクター | |
CN117417962B (zh) | 一种多靶点溶瘤腺病毒的构建方法及应用 | |
Wu et al. | Effective modifications for improved homologous recombination and high-efficiency generation of recombinant adenovirus-based vectors | |
AU2005209653B2 (en) | Adenoviral vectors for treating disease | |
Haviv | A simplified in vitro ligation approach to clone an E1B55k-deleted double-targeted conditionally-replicative adenovirus | |
CN114317462A (zh) | 一种携带TMVP1和tBid的溶瘤腺病毒重组体、其构建方法及应用 | |
AU2005337612A1 (en) | Conditionally replicating viruses and methods for cancer virotherapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |